| Debt | 2021-06-01 | 0 | | O2 Concepts LLC | Newtown, CT
|
| | Debt | Senior Notes | Piper Sandler served as exclusive financial advisor for O2 Concepts, LLC on its debt capital raise | Financial Advisor | | Undisclosed | Healthcare |
| Debt | 2019-12-12 | 0 | | Companion Medical, Inc. | San Diego, CA
|
| Private | Debt | Senior Secured Debt | Piper Sandler served as sole placement agent to Companion Medical, Inc. on securing a debt facility | Financial Advisor | | Undisclosed | Healthcare |
| Debt | 2019-06-28 | 0 | | Saluda Medical Pty Ltd. | Artarmon, NSW
|
| Private | Debt | Senior Secured Debt | Piper Jaffray served as exclusive financial advisor to Saluda Medical on securing a four-year term loan from Medtronic | Financial Advisor | | Undisclosed | Healthcare |
| Debt | 2019-02-21 | 37.5 | | Ocular Therapeutix, Inc. | Bedford, MA
|
| Public (Nasdaq:OCUL) | Debt | Subordinated Debt | Piper Jaffray served as sole placement agent on a $37.5 million subordinated convertible debt financing | Sole Placement Agent | | 37.5 | Healthcare |
| Debt | 2019-01-25 | 25.0 | | Sight Sciences, Inc. | Menlo Park, CA
|
| Private | Debt | Senior Secured Debt | Piper Jaffray served as sole debt placement agent to Sight Sciences, Inc. on debt capital raise | Sole Financial Advisor | | 25.0 | Healthcare |
| Debt | 2019-01-08 | 0 | | Musculoskeletal Clinical Regulatory Advisors, LLC | ,
|
| Private | Debt | Senior Secured Debt | Piper Jaffray served as sole placement agent for Musculoskeletal Clinical Regulatory Advisers, LLC on debt capital raise | Sole Financial Advisor | | Undisclosed | Healthcare |
| Debt | 2018-06-20 | 0 | | ECG Management Consultants, Inc. | Seattle, WA
|
| Gryphon Investors | Debt | Senior Secured Debt | Piper Jaffray served as exclusive financial advisor and sole debt placement agent to ECG Management Consultants, Inc. on debt capital raise | Financial Advisor | | Undisclosed | Healthcare |
| Debt | 2018-03-22 | 579.6 | | Accelerate Diagnostics, Inc. | Tucson, AZ
|
| Public (Nasdaq:ASDX) | Debt | Senior Secured Debt | Piper Jaffray served as co-financial advisor for Accelerate Diagnostics, Inc. on March 2018 convertible offering | Financial Advisor | | 579.6 | Healthcare |
| Debt | 2017-12-27 | 40.0 | | AEGEA Medical Inc. | Redwood City, CA
|
| Private | Debt | Senior Secured Debt | Piper Jaffray served as sole placement agent on capital raise for AEGEA Medical Inc. | Sole Placement Agent | | 40.0 | Healthcare |
| Debt | 2017-12-18 | 58.5 | | Respicardia, Inc. | Hopkins, MN
Develops implantable therapies that are designed to improve respiratory rhythm management and cardiovascular health in heart failure patients |
| Private | Debt | Project Finance | Piper Jaffray served as exclusive financial advisor for Respicardia, Inc. on debt financing from ZOLL Medical | Financial Advisor | | 58.5 | Healthcare |
| Debt | 2017-11-20 | 100.0 | | Recro Pharma, Inc. | Malvern, PA
|
| Public (Nasdaq:REPH) | Debt | Senior Secured Debt | Piper Jaffray served as exclusive financial adviser and sole placement agent to Recro Pharma on capital raise by Athyrium Capital Management, LLC | Financial Advisor | | 100.0 | Healthcare |
| Debt | 2017-07-17 | 200.0 | | Availty, LLC | Jacksonville, FL
Availity, LLC develops network software which provides information exchange between various healthcare stakeholders. It connects care providers with various health plans through an Internet-based and HIPAA-compliant network that allows for automation of b |
| Private | Debt | Senior Secured Debt | Piper Jaffray served as sole financial advisor for Availty, LLC on debt capital raise. | Financial Advisor | | 200.0 | Healthcare |
| Debt | 2017-06-26 | 240.0 | | Humanwell Healthcare (Group) Co., Ltd. | Wuhan,
|
| Public (SHA:600079) | Debt | Senior Secured Debt | Piper Jaffray served as the sole financial advisor on debt capital raise for Humanwell Healthcare. | Financial Advisor | | 240.0 | Healthcare |
| Debt | 2017-05-22 | 10.0 | | Sotera Wireless, Inc. | San Diego, CA
Develops, markets and sells a vital signs monitoring solution. The company offers ViSi mobile system, a platform for comprehensive vital signs monitoring that is designed to keep clinicians connected to their patients. |
| Private | Debt | Senior Secured Debt | $10 million capital raise to recap and reorganize the business. | Financial Advisor | | 10.0 | Healthcare |
| Debt | 2017-05-12 | 50.0 | | Cardiome Pharma Corp. | Vancouver, CAN
Product-focused cardiovascular drug development company with clinical drug programs. The company's programs focus on atrial arrhythmia and congestive heart failure. |
| Public (TSX:COM) | Debt | Senior Secured Debt | $50 million debt capital raise | Financial Advisor | | 50.0 | Healthcare |
| Debt | 2017-04-28 | 20.0 | | 4WEB Inc. | Frisco, TX
Private orthopedic implant company that has developed and commercialized disruptive products for spine, foot and ankle and trauma (patient specific implants) procedures. |
| Private | Debt | Senior Secured Debt | Raised $20 million of debt from a family office to support strategic growth initiatives | Sole Placement Agent | | 20.0 | Healthcare |
| Debt | 2017-03-14 | 0 | | PromptCare Inc | Clark, NJ
Provides home-based specialty respiratory and infusion therapy services. |
| Private | Debt | Senior Secured Debt | Capital raise to support sale to The Halifax Group | Sole Placement Agent | | Undisclosed | Healthcare |
| Debt | 2017-01-11 | 60.0 | | Novadaq Technologies Inc. | Mississauga, Ontario,
A leading medical technology company based in Ontario, Canada. |
| Public (TSX:NDQ) | Debt | Senior Secured Debt | $60M debt capital raise from MidCap Financial Services | Sole Placement Agent | | 60.0 | Healthcare |
| Debt | 2016-02-11 | 0 | | Vizient, Inc. | Irving, TX
Operates a network of not-for-profit health care organizations to improve performance and efficiency in clinical, financial, and operational management. |
| Private | Debt | Senior Secured Debt | Raised transaction financing to support acquisition of MedAssets' Spend and Clinical Resource Management segment. | Financial Advisor | | Undisclosed | Healthcare |
| Debt | 2016-02-01 | 0 | | Sancilo & Company, Inc. | Riviera Beach, FL
Develops, commercializes, and manufactures branded, over-the-counter, and generic prescription pharmaceutical products. |
| Private | Debt | Senior Secured Debt | Raise private senior secured term loan facility from MidCap Financial Services, LLC. | Financial Advisor | | Undisclosed | Healthcare |
| Debt | 2015-04-13 | 100.0 | | Cipher Pharmaceuticals Inc | Mississauga, Ontario,
Operates as a specialty pharmaceutical company that commercializes novel formulations of marketed molecules. |
| Public (TSX:CPH) | Debt | Senior Secured Debt | Announced $100 million senior secured capital raise to finance the acquisition of INNOCUTIS Holdings LLC | Financial Advisor | | 100.0 | Healthcare |
| Debt | 2014-05-30 | 80.0 | | Small Bone Innovations, Inc. | New York, NY
Manufactures and supplies orthopedics devices and instruments to treat trauma and diseases in small bones and joints |
| Private | Debt | Senior Secured Debt | $80 million senior secured debt financing | Financial Advisor & Placement Agent | | 80.0 | Healthcare |
| Debt | 2013-10-29 | 50.0 | | Apollo Endosurgery, Inc. | Austin, TX
Offers a product suite of surgical products from the convergence of laparoscopic surgery and therapeutic gastroenterology. |
| Private | Debt | Senior Secured Debt | $50 million senior securred debt financing | Financial Advisor & Placement Agent | | 50.0 | Healthcare |
| Equity | 2021-07-02 | 97.8 | | Nyxoah S.A. | Mont-Saint-Guibert, BE
|
| Public(EBR:NYXH) | Equity | Initial Public Offering | Piper Sandler served as lead left bookrunner for Nyxoah SA on its July 2021 initial public offering | Lead Bookrunner | EBR:NYXH | 97.8 | Healthcare |
| Equity | 2021-06-30 | 83.6 | | Aligos Therapeutics | South San Francisco, CA
|
| Public(Nasdaq:ALGS) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Aligos Therapeutics, Inc. on its June 2021 follow-on offering | Joint Bookrunner | Nasdaq:ALGS | 83.6 | Healthcare |
| Equity | 2021-06-29 | 144.9 | | CVRx, Inc. | Minneapolis, MN
|
| Johnson & Johnson Innovation | Equity | Initial Public Offering | Piper Sandler served as bookrunner for CVRx, Inc. on its June 2021 initial public offering | Joint Bookrunner | Nasdaq:CVRX | 144.9 | Healthcare |
| Equity | 2021-06-23 | 222.3 | | Monte Rosa Therapeutics | Basel, BS
|
| | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Monte Rosa Therapeutics, Inc. on its June 2021 initial public offering | Joint Bookrunner | | 222.3 | Healthcare |
| Equity | 2021-06-23 | 1002.0 | | Bright Health Inc. | Minneapolis, MN
|
| Public(NYSE:BHG) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Bright Health Group, Inc. on its June 2021 initial public offering | Passive Bookrunner | NYSE:BHG | 1002.0 | Healthcare |
| Equity | 2021-06-23 | 696.6 | | Doximity, Inc. | San Francisco, CA
|
| InterWest Partners LLC | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Doximity, Inc. on its June 2021 initial public offering | Passive Bookrunner | NYSE:DOCS | 696.6 | Healthcare |
| Equity | 2021-04-28 | 515.7 | | Privia Health LLC | Arlington, VA
|
| Brighton Health Partners LLC | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Privia Health Group, Inc. on it's April 2021 initial public offering | Joint Bookrunner | Nasdaq:PRVA | 515.7 | Healthcare |
| Equity | 2021-04-22 | 28.0 | EDAP TMS SA | Public(Nasdaq:EDAP) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as sole bookrunner for EDAP TMS S.A. on its April 2021 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:EDAP | 28.0 | Healthcare |
| Equity | 2021-04-22 | 124.9 | | Rain Therapeutics | Newark, CA
|
| Public(Nasdaq:RAIN) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Rain Therapeutics, Inc. on its April 2021 initial public offering | Joint Bookrunner | Nasdaq:RAIN | 124.9 | Healthcare |
| Equity | 2021-04-15 | 151.3 | | Akoya Biosciences, Inc. | Marlborough, MA
|
| Public(Nasdaq:AKYA) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Akoya Biosciences, Inc. on its April 2021 initial public offering | Joint Bookrunner | Nasdaq:AKYA | 151.3 | Healthcare |
| Equity | 2021-04-15 | 153.0 | | Biomea Fusion | Redwood City, CA
|
| Public(Nasdaq:BMEA) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Biomea Fusion, Inc. on its April 2021 initial public offering | Joint Bookrunner | Nasdaq:BMEA | 153.0 | Healthcare |
| Equity | 2021-04-15 | 100.9 | | SeaSpine Holdings Corporation | Carlsbad, CA
|
| Public(Nasdaq:SPNE) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as lead left bookrunner for SeaSpine Holdings Corporation on its April 2021 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:SPNE | 100.9 | Healthcare |
| Equity | 2021-04-08 | 93.7 | | Reneo Pharmaceuticals | San Diego, CA
|
| Public(Nasdaq:RPHM) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Reneo Pharmaceuticals, Inc. on it's April 2021 initial public offering | Joint Bookrunner | Nasdaq:RPHM | 93.7 | Healthcare |
| Equity | 2021-04-07 | 34.6 | | Otonomy, Inc. | San Diego, CA
|
| Public(Nasdaq:OTIC) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Otonomy, Inc. on its April 2021 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:OTIC | 34.6 | Healthcare |
| Equity | 2021-04-07 | 258.7 | Phreesia Inc. | Public(NYSE:PHR) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Phreesia, Inc. on its April 2021 follow-on offering | Passive Bookrunner | NYSE:PHR | 258.7 | Healthcare |
| Equity | 2021-03-30 | 175.0 | | Achilles Therapeutics | London, GB
|
| | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Achilles Therapeutics, Inc. on it's March 2021 initial public offering | Joint Bookrunner | Nasdaq:ACHL | 175.0 | Healthcare |
| Equity | 2021-03-25 | 549.0 | | Alignment Healthcare LLC | Orange, CA
|
| | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Alignment Healthcare, Inc. on its March 2021 initial public offering | Passive Bookrunner | Nasdaq:ALHC | 549.0 | Healthcare |
| Equity | 2021-03-25 | 276.0 | | Design Therapeutics | Carlsbad, CA
|
| | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Design Therapeutics, Inc. on its March 2021 initial public offering | Joint Bookrunner | Nasdaq:DSGN | 276.0 | Healthcare |
| Equity | 2021-03-24 | 287.0 | | Accolade, Inc | Plymouth Meeting, PA
|
| | Equity | Convertible | Piper Sandler served as bookrunner for Accolade, Inc. on its senior unsecured convertible notes offering | Passive Bookrunner | Nasdaq:ACCD | 287.0 | Healthcare |
| Equity | 2021-03-18 | 219.0 | | Connect Biopharma | Taicang, JS
|
| | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Connect Biopharma Holdings Limited on its March 2021 initial public offering | Joint Bookrunner | Nasdaq:CNTB | 219.0 | Healthcare |
| Equity | 2021-03-18 | 143.7 | | Solid Biosciences Inc. | Cambridge, MA
|
| | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Solid Biosciences, Inc. on its March 2021 follow-on offering | Joint Bookrunner | Nasdaq:SLDB | 143.7 | Healthcare |
| Equity | 2021-03-11 | 56.0 | | Marker Therapeutics, Inc. | Houston, TX
|
| Public(Nasdaq:MRKR) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as sole bookrunner for Marker Therapeutics, Inc. on its March 2021 confidentially marketed follow-on offering | Sole Bookrunner | Nasdaq:MRKR | 56.0 | Healthcare |
| Equity | 2021-03-11 | 129.0 | Savara Inc. | Public(Nasdaq:SVRA) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Savara, Inc. on its March 2021 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:SVRA | 129.0 | Healthcare |
| Equity | 2021-03-11 | 920.0 | | Oak Street Health, LLC | Chicago, IL
|
| Public(NYSE:OSH) | Equity | Convertible | Piper Sandler served as co-manager for Oak Street Health, LLC on its convertible offering | Co-Manager | NYSE:OSH | 920.0 | Healthcare |
| Equity | 2021-03-09 | 65.0 | | Jounce Therapeutics, Inc. | Cambridge, MI
|
| Public(Nasdaq:JNCE) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Jounce Therapeutics, Inc. on its March 2021 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:JNCE | 65.0 | Healthcare |
| Equity | 2021-03-08 | 200.0 | | Vocera Communications, Inc. | San Jose, CA
|
| Public(NYSE:VCRA) | Equity | Convertible | Piper Sandler served as bookrunner for Vocera Communication, Inc. on March 2021 senior unsecured convertible note offering | Joint Bookrunner | NYSE:VCRA | 200.0 | Healthcare |
| Equity | 2021-03-04 | 160.0 | | Nurix Inc. | San Francisco, CA
|
| Public(Nasdaq:NRIX) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Nurix Therapeutics Inc. on its March 2021 follow-on offering | Joint Bookrunner | Nasdaq:NRIX | 160.0 | Healthcare |
| Equity | 2021-02-11 | 92.0 | | Infinity Pharmaceuticals, Inc. | Cambridge, MA
|
| Public(NASDAQ:INFI) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as sole bookrunner for Infinity Pharmaceuticals, Inc. on February 2021 confidentially marketed follow-on offering | Lead Bookrunner | NASDAQ:INFI | 92.0 | Healthcare |
| Equity | 2021-02-11 | 57.0 | | Oncorus, Inc. | Cambridge, MA
|
| Public(NASDAQ:ONCR) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Oncorus, Inc. on February 2021 follow-on offering | Joint Bookrunner | NASDAQ:ONCR | 57.0 | Healthcare |
| Equity | 2021-02-11 | 254.0 | | Talis Biomedical | Menlo Park, CA
|
| Public(NASDAQ:TLIS) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Talis Biomedical Corporation on their February 2021 initial public offering | Passive Bookrunner | NASDAQ:TLIS | 254.0 | Healthcare |
| Equity | 2021-02-10 | 173.0 | | Apria Healthcare Group Inc. | Lake Forest, CA
|
| The Blackstone Group L.P. | Equity | Initial Public Offering | Piper Sandler served as co-manager for Apria, Inc. on its February 2021initial public offering | Co-Manager | NASDAQ:APR | 173.0 | Healthcare |
| Equity | 2021-02-10 | 691.0 | | Oak Street Health, LLC | Chicago, IL
|
| Public(NYSE:OSH) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Oak Street Health, LLC on its February 2021 follow-on offering | Passive Bookrunner | NYSE:OSH | 691.0 | Healthcare |
| Equity | 2021-02-10 | 649.0 | | Signify Health | Dallas, TX, DE
|
| New Mountain Capital, LLC | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Signify Health on it's February 2021 initial public offering | Passive Bookrunner | NYSE:SGFY | 649.0 | Healthcare |
| Equity | 2021-02-08 | 204.0 | | I-Mab Biopharma | Shanghai, CN
|
| Public(NASDAQ:I-MAB) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for I-MAB Biopharma on its February 2021 follow-on offering | Joint Bookrunner | NASDAQ:I-MAB | 204.0 | Healthcare |
| Equity | 2021-02-05 | 80.0 | | Itamar Medical | Caesarea, IL
|
| Public(NASDAQ:ITMR) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as left bookrunner for Itamar Medical Ltd. on February 2021 confidentially marketed follow-on offering | Lead Bookrunner | NASDAQ:ITMR | 80.0 | Healthcare |
| Equity | 2021-02-04 | 41.0 | | OncoCyte Corporation | Irvine, CA
|
| Public(NYSE:OCX) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as sole bookrunner for OncoCyte Corporation on February 2021 confidentially marketed follow-on offering | Lead Bookrunner | NYSE:OCX | 41.0 | Healthcare |
| Equity | 2021-02-03 | 69.0 | | Kaleido Biosciences | Lexington, MA
|
| Public(NASDAQ:KLDO) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Kaleido Biosciences, Inc. on its February 2021 confidentially marketed follow-on offering | Joint Bookrunner | NASDAQ:KLDO | 69.0 | Healthcare |
| Equity | 2021-02-03 | 153.0 | | Sensei Biotherapeutics, Inc. | Gaithersburg, MA
|
| Public(NASDAQ:SNSE) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Sensei Biotherapeutics Inc. on its February 2021 initial public offering | Joint Bookrunner | NASDAQ:SNSE | 153.0 | Healthcare |
| Equity | 2021-01-28 | 86.0 | | Neuronetics, Inc. | Malvern, PA
|
| Public(NASDAQ:STIM) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Neuronetics, Inc. on its January 2021 confidentially marketed follow-on offering | Joint Bookrunner | NASDAQ:STIM | 86.0 | Healthcare |
| Equity | 2021-01-27 | 1485.0 | | Ortho-Clinical Diagnostics, Inc. | Raritan, NJ
|
| The Carlyle Group | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Ortho-Clinical Diagnostics, Inc. on its January 2021 initial public offering | Passive Bookrunner | NASDAQ:OCDX | 1485.0 | Healthcare |
| Equity | 2021-01-27 | 43.0 | | Surgalign Holdings, Inc. | Deerfield, IL
|
| Public(NASDAQ:SRGA) | Equity | Follow-On Offering | Piper Sandler served as lead left bookrunner for Suralign Holdings, Inc. on its January 2021 follow-on offering | Joint Bookrunner | NASDAQ:SRGA | 43.0 | Healthcare |
| Equity | 2021-01-26 | 53.0 | | Catalyst Biosciences, Inc. | South San Francisco, CA
|
| Public(NASDAQ:CBIO) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as sole bookrunner for Catalyst Biosciences, Inc. on its January 2021 confidentially marketed follow-on offering | Lead Bookrunner | NASDAQ:CBIO | 53.0 | Healthcare |
| Equity | 2021-01-25 | 747.0 | | BridgeBio Pharma, Inc. | Palo Alto, CA
|
| Public(NASDAQ:BBIO) | Equity | Convertible | Piper Sandler served as bookrunner for BridgeBio Pharma, Inc. on it convertible senior note offering | Passive Bookrunner | NASDAQ:BBIO | 747.0 | Healthcare |
| Equity | 2021-01-21 | 230.0 | | SCP & Co. Healthcare Acquisition Company | Tampa, FL
|
| Public(NASDAQ:SHACU) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for SCP & Co. Healthcare Acquisition Company on January 2021 initial public offering | Joint Bookrunner | NASDAQ:SHACU | 230.0 | Healthcare |
| Equity | 2021-01-20 | 115.0 | | CytomX Therapeutics Inc. | South San Francisco, CA
|
| Public(NASDAQ:CTMX) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for CytomX Therapeutics, Inc, on January 2021 follow-on offering | Joint Bookrunner | NASDAQ:CTMX | 115.0 | Healthcare |
| Equity | 2021-01-20 | 168.0 | | Dyne Therapeutics Inc. | Waltham, MA
|
| Public(NASDAQ:DYN) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Dyne Therapeutics, Inc. on January 2021 follow-on offering | Joint Bookrunner | NASDAQ:DYN | 168.0 | Healthcare |
| Equity | 2021-01-19 | 51.0 | | Fulcrum Therapeutics, Inc. | Cambridge, MA
|
| Public(NASDAQ:FULC) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Fulcrum Therapeutics Inc. on January 2021 confidentially marketed follow-on offering | Joint Bookrunner | NASDAQ:FULC | 51.0 | Healthcare |
| Equity | 2021-01-19 | 76.0 | | Syros Pharmaceuticals, Inc. | Cambridge, MA
|
| Public(NASDAQ:SYRS) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Syros Pharmaceuticals, Inc. on January 2021 confidentially marketed follow-on offering | Joint Bookrunner | NASDAQ:SYRS | 76.0 | Healthcare |
| Equity | 2021-01-19 | 140.0 | | TCR2 Therapeutics | Cambridge, MA
|
| Public(NASDAQ:TCRR) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for TCR2 Therapeutics, Inc. on January follow-on offering | Joint Bookrunner | NASDAQ:TCRR | 140.0 | Healthcare |
| Equity | 2021-01-14 | 357.0 | | American Well Corporation | Boston, MA
|
| Public(NYSE:AMWL) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for American Well Corporation on January 2021 follow-on offering | Joint Bookrunner | NYSE:AMWL | 357.0 | Healthcare |
| Equity | 2021-01-07 | 240.0 | Gracell Bio | Public(NASDAQ:GRCL) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Gracell Biotechnologies Inc. on January 2021 initial public offering | Joint Bookrunner | NASDAQ:GRCL | 240.0 | Healthcare |
| Equity | 2021-01-06 | 115.0 | | Harpoon Therapeutics, Inc. | South San Francisco, CA
|
| Public(NASDAQ:HARP) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Harpoon Therapeutics, Inc. on January 2020 initial public offering | Joint Bookrunner | NASDAQ:HARP | 115.0 | Healthcare |
| Equity | 2021-01-04 | 57.0 | ViewRay Inc. | Public(NASDAQ:VRAY) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as sole bookrunner for ViewRay Inc. on January 2021 confidentially marketed follow-on offering | Lead Bookrunner | NASDAQ:VRAY | 57.0 | Healthcare |
| Equity | 2020-10-27 | 875.0 | | Mirati Therapeutics, Inc. | San Diego, CA
|
| Public(Nasdaq:MRTX) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Mirati Therapeutics, Inc. on October 2020 follow-on offering | Passive Bookrunner | Nasdaq:MRTX | 875.0 | Healthcare |
| Equity | 2020-10-22 | 52.0 | | Milestone Pharmaceuticals Inc. | Montreal, BC
|
| Public(Nasdaq:MIST) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Milestone Pharmaceuticals, Inc. on October 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:MIST | 52.0 | Healthcare |
| Equity | 2020-10-21 | 221.0 | | Accolade, Inc | Plymouth Meeting, PN
|
| Public(Nasdaq:ACCD) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Accolade, Inc. on October 2020 follow-on offering | Passive Bookrunner | Nasdaq:ACCD | 221.0 | Healthcare |
| Equity | 2020-10-21 | 48.0 | Aptinyx Inc. | Public(Nasdaq:APTX) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Aptinyx, Inc. on October 2020 follow-on offering | Joint Bookrunner | Nasdaq:APTX | 48.0 | Healthcare |
| Equity | 2020-10-20 | 184.0 | | Phreesia Inc. | New York, NY
|
| Public(NYSE:PHR) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Phreesia Inc. on October 2020 follow-on offering | Passive Bookrunner | NYSE:PHR | 184.0 | Healthcare |
| Equity | 2020-10-15 | 219.0 | | Praxis Precision Medicines | Cambridge, MA
|
| Public(Nasdaq:PRAX) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Praxis Precision Medicines, Inc. on October 2020 initial public offering | Joint Bookrunner | Nasdaq:PRAX | 219.0 | Healthcare |
| Equity | 2020-10-15 | 150.0 | | Aligos Therapeutics | South San Francisco, CA
|
| Public(NYSE:ALG) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Aligos Therapeutics on its October 2020 initial public offering | Joint Bookrunner | NYSE:ALG | 150.0 | Healthcare |
| Equity | 2020-10-13 | 81.0 | | Ocular Therapeutix, Inc. | Bedford, MA
|
| Public(Nasdaq:OCUL) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Ocular Therapeutix, Inc. on October 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:OCUL | 81.0 | Healthcare |
| Equity | 2020-10-08 | 288.0 | Kronos Bio | Public(NYSE:KRO) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Kronos Bio on October 2020 initial public offering | Joint Bookrunner | NYSE:KRON | 288.0 | Healthcare |
| Equity | 2020-10-07 | 50.0 | | Aziyo Biologics, Inc. | Silver Spring, MD
|
| Public(Nasdaq:AZYO) | Equity | Initial Public Offering | Piper Sandler served as lead bookrunner for Aziyo Biologics, Inc. on October 2020 initial public offering | Lead Bookrunner | NASDAQ:AZYO | 50.0 | Healthcare |
| Equity | 2020-10-01 | 98.0 | | Oncorus, Inc. | Cambridge, MA
|
| Public(Nasdaq:ONC) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Oncorus, Inc. on October 2020 initial public offering | Joint Bookrunner | NASDAQ:ONCR | 98.0 | Healthcare |
| Equity | 2020-09-29 | 101.0 | | Cardiff Oncology, Inc. | San Diego, CA
|
| Public(Nasdaq:CRDF) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Cardiff Oncology, Inc. on September 2020 confidentially marketed follow-on offering | Joint Bookrunner | NASDAQ:CRDF | 101.0 | Healthcare |
| Equity | 2020-09-24 | 90.0 | | Graybug Vision, Inc. | Redwood City, CA
|
| Public(Nasdaq:GRAY) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Graybug Vision, Inc. on September 2020 initial public offering | Joint Bookrunner | NASDAQ:GRAY | 90.0 | Healthcare |
| Equity | 2020-09-16 | 233.0 | | Dyne Therapeutics Inc. | Waltham, MA
|
| Public(Nasdaq:DYN) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Dyne Therapeutics Inc. on September 2020 initial public offering | Joint Bookrunner | NASDAQ:DYN | 233.0 | Healthcare |
| Equity | 2020-09-16 | 742.0 | | American Well Corporation | Boston, MA
|
| Public(NYSE:AMWL) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for American Well Corporation on September 2020 initial public offering | Joint Bookrunner | NYSE:AMWL | 742.0 | Healthcare |
| Equity | 2020-08-18 | 148.0 | | Harmony Biosciences Holdings, Inc. | Plymouth Meeting, Pennsylvania
|
| Public(Nasdaq:HRMY) | Equity | Initial Public Offering | Piper Sandler served as active bookrunner for Harmony Biosciences Holdings, Inc. on August 2020 initial public offering | Joint Bookrunner | NASDAQ:HRMY | 148.0 | Healthcare |
| Equity | 2020-08-13 | 377.3 | | Oak Street Health, LLC | Chicago, Illinois
|
| General Atlantic | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Oak Street Health, Inc. on August 2020 initial public offering | Joint Bookrunner | NYSE:OSH | 377.3 | Healthcare |
| Equity | 2020-08-12 | 216.7 | | Adverum Biotechnologies, Inc. | Redwood City, California
|
| Public(Nasdaq:ADVM) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Adverum Biotechnologies, Inc. on August 2020 follow-on offering | Joint Bookrunner | Nasdaq:ADVM | 216.7 | Healthcare |
| Equity | 2020-08-12 | 225.8 | | Seres Therapeutics, Inc. | Cambridge, Massachusetts
|
| Public(Nasdaq:MCRB) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Seres Therapeutics, Inc. on August 2020 follow-on offering | Joint Bookrunner | Nasdaq:MCRB | 225.8 | Healthcare |
| Equity | 2020-08-06 | 963.5 | | Horizon Therapeutics Public Limited Company | Dublin, Co. Dublin
|
| Public(Nasdaq:HZNP) | Equity | Follow-On Offering | Piper Sandler served as passive bookrunner for Horizon Therapeutics on August 2020 follow-on offering | Passive Bookrunner | Nasdaq:HZNP | 963.5 | Healthcare |
| Equity | 2020-07-31 | 143.0 | | TCR2 Therapeutics | Cambridge, MA
|
| Public(Nasdaq:TCRR) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for TCR2 Therapeutics on July 2020 follow-on offering | Joint Bookrunner | Nasdaq:TCRR | 143.0 | Healthcare |
| Equity | 2020-07-30 | 276.0 | | AlloVir, Inc. | Cambridge, MA
|
| Public(Nasdaq:ALVR) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Allovir, Inc. on July 2020 initial public offering | Joint Bookrunner | Nasdaq:ALVR | 276.0 | Healthcare |
| Equity | 2020-07-23 | 128.0 | | Inozyme Pharma, Inc. | Boston, MA
|
| Public(Nasdaq:INZY) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Inozyme Pharma, Inc. on July 2020 initial public offering | Joint Bookrunner | Nasdaq:INZY | 128.0 | Healthcare |
| Equity | 2020-07-23 | 201.0 | | iTeos Therapeutics SA | Gosselies, BE
|
| Public(Nasdaq:ITOS) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for iTeos Therapeutics on July 2020 initial public offering | Joint Bookrunner | Nasdaq:ITOS | 201.0 | Healthcare |
| Equity | 2020-07-23 | 238.0 | | Nurix Inc. | San Francisco, CA
|
| Public(Nasdaq:NRIX) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Nurix Inc. on July 2020 initial public offering | Joint Bookrunner | Nasdaq:NRIX | 238.0 | Healthcare |
| Equity | 2020-07-16 | 186.0 | | ALX Oncology | Burlingame, CA
|
| Public (Nasdaq:ALXO) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for ALX Oncology Holdings Inc. on July 2020 initial public offering - (Collins/Stadinski/Scansaroli/Riley) | Joint Bookrunner | Nasdaq:ALXO | 186.0 | Healthcare |
| Equity | 2020-07-16 | 201.0 | | Cytokinetics, Incorporated | South San Francisco, CA
|
| Public (Nasdaq:CYTK) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for CytoKinetics, Incorporated on July 2020 follow-on offering | Joint Bookrunner | Nasdaq:CYTK | 201.0 | Healthcare |
| Equity | 2020-07-15 | 55.0 | | Aptose Biosciences Inc. | Toronto, ON
|
| Public (Nasdaq:APS) | Equity | Follow-On Offering | Piper Sandler served as sole bookrunner for Aptose Biosciences Inc. on July 2020 follow-on offering | Lead Bookrunner | Nasdaq:APS | 55.0 | Healthcare |
| Equity | 2020-07-14 | 55.0 | Zynex, Inc. | Public (Nasdaq:ZYXI) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as sole bookrunner for Zynex, Inc. on July 2020 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:ZYXI | 55.0 | Healthcare |
| Equity | 2020-07-13 | 115.0 | | Altimmune, Inc. | Gaithersburg, MD
|
| Public (Nasdaq:ALT) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Altimmune, Inc. on July 2020 initial public offering | Joint Bookrunner | Nasdaq:ALT | 115.0 | Healthcare |
| Equity | 2020-07-09 | 69.0 | | Otonomy, Inc. | San Diego, CA
|
| Public (Nasdaq:OTIC) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Otonomy, Inc. on July 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:OTIC | 69.0 | Healthcare |
| Equity | 2020-07-09 | 224.0 | | Poseida Therapeutics, Inc. | San Diego, CA
|
| Public (Nasdaq:PSTX) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Poseida Therapeutics, Inc. on July 2020 initial public offering | Joint Bookrunner | Nasdaq:PSTX | 224.0 | Healthcare |
| Equity | 2020-07-07 | 403.0 | | Pacira BioSciences, Inc. | Parsippany, NJ
|
| Public (Nasdaq:PCRX) | Equity | Convertible | Piper Sandler served as bookrunner for Pacira Biosciences, Inc. on July 2020 convertible offering | Joint Bookrunner | Nasdaq:PCRX | 403.0 | Healthcare |
| Equity | 2020-07-01 | 254.0 | | Accolade, Inc | Plymouth Meeting, PA
|
| Public (Nasdaq:ACCD) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Accolade, Inc. on July 2020 initial public offering | Joint Bookrunner | Nasdaq:ACCD | 254.0 | Healthcare |
| Equity | 2020-07-01 | 81.0 | Chiasma, Inc. | Public (Nasdaq:CHMA) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Chiasma, Inc. on July 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:CHMA | 81.0 | Healthcare |
| Equity | 2020-07-01 | 76.0 | | Neoleukin Therapeutics | Seattle, WA
|
| Public (Nasdaq:NLTX) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Neoleukin Therapeutics, Inc. on Julu 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:NLTX | 76.0 | Healthcare |
| Equity | 2020-06-30 | 518.0 | | Acceleron Pharma, Inc. | Cambridge, MA
|
| Public (Nasdaq:XLRN) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Acceleron Pharma, Inc. on July 2020 follow-on offering | Joint Bookrunner | Nasdaq:XLRN | 518.0 | Healthcare |
| Equity | 2020-06-25 | 213.0 | Akouos, Inc. | Public (Nasdaq:AKUS) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Akouos, Inc. on June 2020 initial public offering | Joint Bookrunner | Nasdaq:AKUS | 213.0 | Healthcare |
| Equity | 2020-06-25 | 257.0 | | 1Life Healthcare, Inc. | San Francisco, CA
|
| Public (Nasdaq:ONEM) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for 1Life Healthcare, Inc. on June 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:ONEM | 257.0 | Healthcare |
| Equity | 2020-06-25 | 48.0 | | TELA Bio, Inc. | Malvern, PA
|
| Public (Nasdaq:TELA) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for TELA Bio, Inc. on June 2020 follow-on offering | Joint Bookrunner | Nasdaq:TELA | 48.0 | Healthcare |
| Equity | 2020-06-24 | 80.0 | | NantKwest, Inc. | San Diego, CA
|
| Public (Nasdaq:NK) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for NantKwest, Inc. on June 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:NK | 80.0 | Healthcare |
| Equity | 2020-06-19 | 100.0 | | Progenity, Inc. | San Diego, CA
|
| Public (Nasdaq:PROG) | Equity | Initial Public Offering | Piper Sandler served as lead left bookrunner for Progenity, Inc. on June 2020 initial public offering | Lead Bookrunner | Nasdaq:PROG | 100.0 | Healthcare |
| Equity | 2020-06-19 | 220.0 | | Repare Therapeutics Inc. | Montreal, QC
|
| Public (Nasdaq:RPTX) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Repare Therapeutics, Inc. on June 2020 initial public offering | Joint Bookrunner | Nasdaq:RPTX | 220.0 | Healthcare |
| Equity | 2020-06-18 | 25.0 | | Koru Medical Systems | Chester, NY
|
| Public (Nasdaq:REPR) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Koru Medical Systems (fka Repro-Med Systems, Inc.) on June 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:REPR | 25.0 | Healthcare |
| Equity | 2020-06-17 | 75.0 | | OrthoPediatrics Corp. | Warsaw, IN
|
| Public (Nasdaq:KIDS) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as lead left bookrunner for OrthoPediatrics Corp. on June 2020 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:KIDS | 75.0 | Healthcare |
| Equity | 2020-06-17 | 40.0 | | Leap Therapeutics | Cambridge, MA
|
| Public (Nasdaq:LPTX) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as lead left bookrunner for Leap Therapeutics, Inc. on June 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:LPTX | 40.0 | Healthcare |
| Equity | 2020-06-10 | 301.0 | | ChemoCentryx, Inc. | Mountain View, CA
|
| Public(Nasdaq:CCXI) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for ChemoCentryx, Inc. on June 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:CCXI | 301.0 | Healthcare |
| Equity | 2020-06-08 | 250.0 | | Glaukos Corporation | San Clemente, CA
|
| Public(NYSE:GKOS) | Equity | Convertible | Piper Sandler served as co-manager for Glaukos Corp. on June 2020 convertible senior note offering | Co-Manager | NYSE:GKOS | 250.0 | Healthcare |
| Equity | 2020-06-04 | 50.0 | | Menlo Therapeutics Inc. | Redwood City, CA
|
| Public(Nasdaq:MNLO) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Menlo Therapeutics Inc. on June 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:MNLO | 50.0 | Healthcare |
| Equity | 2020-06-02 | 99.7 | | Evofem Biosciences, Inc. | San Diego, CA
|
| Public(Nasdaq:EVFM) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Evofem Biosciences, Inc. on June 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:EVFM | 99.7 | Healthcare |
| Equity | 2020-06-02 | 144.0 | | Pliant Therapeutics, Inc. | South San Francisco, CA
|
| Public(Nasdaq:PLRX) | Equity | Initial Public Offering | Piper Sandler served as bookrunner for Pliant Therapeutics, Inc. on June 2020 initial public offering | Joint Bookrunner | Nasdaq:PLRX | 144.0 | Healthcare |
| Equity | 2020-06-01 | 550.0 | | Allogene Therapeutics, Inc. | South San Francisco, CA
|
| Public(Nasdaq:ALLO) | Equity | Convertible | Piper Sandler served as bookrunner for Allogene Therapeutics, Inc. on June 2020 convertible offering | Passive Bookrunner | Nasdaq:ALLO | 550.0 | Healthcare |
| Equity | 2020-06-01 | 475.0 | | Livongo Health Inc. | Mountain View, CA
|
| Public(Nasdaq:LVGO) | Equity | Convertible | Piper Sandler served as co-manager for Livongo Health Inc. on June 2020 convertible offering | Co-Manager | Nasdaq:LVGO | 475.0 | Healthcare |
| Equity | 2020-05-27 | 100.0 | | BioCryst Pharmaceuticals, Inc. | Durham, NC
|
| Public(Nasdaq:BCRX) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for BioCryst Pharmaceuticals, Inc. on May 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:BCRX | 100.0 | Healthcare |
| Equity | 2020-05-26 | 275.0 | | 1Life Healthcare, Inc. | San Francisco, CA
|
| Public(Nasdaq:ONEM) | Equity | Convertible | Piper Sandler served as co-manager for 1Life Healthcare, Inc. on May 2020 convertible offering | Co-Manager | Nasdaq:ONEM | 275.0 | Healthcare |
| Equity | 2020-05-20 | 570.0 | | SelectQuote Insurance Services, Inc. | San Francisco, CA
|
| Public(NYSE:SLQT) | Equity | Initial Public Offering | Piper Sandler served as co-manager for SelectQuote, Inc. on May 2020 initial public offering | Co-Manager | NYSE:SLQT | 570.0 | Healthcare |
| Equity | 2020-05-19 | 45.0 | | Ocular Therapeutix, Inc. | Bedford, MA
|
| Public(Nasdaq:OCUL) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Ocular Therapeutic, Inc. on May 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:OCUL | 45.0 | Healthcare |
| Equity | 2020-05-18 | 60.0 | | Gamida Cell Ltd. | Jerusalem, IL
|
| Public(Nasdaq:GMDA) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Gamida Cell Ltd. on May 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:GMDA | 60.0 | Healthcare |
| Equity | 2020-05-18 | 200.0 | | Gossamer Bio | San Diego, CA
|
| Public(Nasdaq:GOSS) | Equity | Convertible | Piper Sandler served as bookrunner for Gossamer Bio, Inc. on May 2020 convertible senior note offering | Joint Bookrunner | Nasdaq:GOSS | 200.0 | Healthcare |
| Equity | 2020-05-14 | 105.0 | | Oyster Point Pharma, Inc. | Princeton, NJ
|
| Public(Nasdaq:OYST) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Oyster Point Pharma, Inc. on May 2020 follow-on offering | Joint Bookrunner | Nasdaq:OYST | 105.0 | Healthcare |
| Equity | 2020-05-11 | 132.0 | | Akebia Therapeutics, Inc. | Cambridge, MA
|
| Public(Nasdaq:AKBA) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Akebia Therapeutics on confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:AKBA | 132.0 | Healthcare |
| Equity | 2020-05-11 | 175.0 | AtriCure, Inc. | Public(Nasdaq:ATRC) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for AtriCure, Inc. on May 2020 follow-on offering | Joint Bookrunner | Nasdaq:ATRC | 175.0 | Healthcare |
| Equity | 2020-05-11 | 85.3 | | Sutro Biopharma, Inc. | San Francisco, CA
|
| Public(Nasdaq:STRO) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as bookrunner for Sutro Biopharma, Inc. on May 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:STRO | 85.3 | Healthcare |
| Equity | 2020-04-28 | 120.0 | | Aeglea BioTherapeutics | Austin, TX
|
| Public(Nasdaq:AGLE) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as active bookrunner for Aeglea BioTherapeutics, Inc. on April 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:AGLE | 120.0 | Healthcare |
| Equity | 2020-04-28 | 125.0 | | Avadel Pharmaceuticals | Dublin, IE
|
| Public(Nasdaq:AVDL) | Equity | Follow-On Offering | Piper Sandler served as bookrunner for Avadel Pharmaceuticals PLC on April 2020 follow-on offering | Joint Bookrunner | Nasdaq:AWK1 | 125.0 | Healthcare |
| Equity | 2020-04-28 | 483.0 | | Immunomedics Inc. | Morris Plains, NJ
|
| Public(Nasdaq:IMMU) | Equity | Follow-On Offering | Piper Sandler served as co-manager for Immunomedics Inc. on May 2020 follow-on offering | Co-Manager | Nasdaq:IMMU | 483.0 | Healthcare |
| Equity | 2020-04-17 | 100.1 | | Crinetics Pharmaceuticals, Inc. | San Diego, CA
|
| Public(Nasdaq:CRNX) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as active bookrunner for Piper Sandler on April 2020 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:CRNX | 100.1 | Healthcare |
| Equity | 2020-04-17 | 25.0 | Cutera, Inc. | Public(Nasdaq:CUTR) | Equity | Follow-On Offering | Piper Sandler served as sole manager for Cutera, Inc. on April 2020 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:CUTR | 25.0 | Healthcare |
| Equity | 2020-04-08 | 200.0 | | Health Catalyst, LLC | Salt Lake City, UT
|
| Public(Nasdaq:HCAT) | Equity | Convertible | Piper Sandler served as passive bookrunner for Health Catalyst, LLC on April 2020 convertible offering | Joint Bookrunner | Nasdaq:HCAT | 200.0 | Healthcare |
| Equity | 2020-04-07 | 96.0 | | Keros Therapeutics | Lexington, MA
|
| Public(Nasdaq:KROS) | Equity | Initial Public Offering | Piper Sandler served as active bookrunner for Keros Therapeutics on April 2020 initial public offering | Joint Bookrunner | Nasdaq:KROS | 96.0 | Healthcare |
| Equity | 2020-02-24 | 65.0 | | Avadel Pharmaceuticals | Dublin, IRL
|
| Public(Nasdaq:AVDL) | Equity | PIPE | Piper Sandler served as lead placement agent for Avadel Pharmaceuticals PLC on series A preferred share offering | Joint Bookrunner | Nasdaq:AVDL | 65.0 | Healthcare |
| Equity | 2020-02-14 | 500.0 | | Moderna Therapeutics, Inc. | , MA
|
| Public(Nasdaq:RVNC) | Equity | Follow-On Offering | Piper Sandler served as passive bookrunner for Moderna, Inc. on February 2020 follow-on offering | Joint Bookrunner | Nasdaq:MRNA | 500.0 | Healthcare |
| Equity | 2020-02-11 | 37.4 | | Xeris Pharmaceuticals, Inc. | Austin, TX
|
| | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as active bookrunner for Xeris Pharmaceuticals Inc. on February 2020 follow-on offering | Lead Bookrunner | | 37.4 | Healthcare |
| Equity | 2020-02-11 | 250.0 | | Revance Therapeutics, Inc. | Newark, CA
|
| Public(Nasdaq:RVNC) | Equity | Convertible | Piper Sandler served as co-manager for Revance Therapeutics, Inc. on February 2020 convertible offering | Co-Manager | Nasdaq:RVNC | 250.0 | Healthcare |
| Equity | 2020-01-30 | 245.0 | | 1Life Healthcare, Inc. | New York, NY
|
| Public(Nasdaq:ONEM) | Equity | Initial Public Offering | Piper Sandler served as passive bookrunner for 1LIfe Healthcare, Inc. on initial public offering | Joint Bookrunner | Nasdaq:ONEM | 245.0 | Healthcare |
| Equity | 2020-01-09 | 50.0 | | Matinas BioPharma Holdings, Inc. | Bedminster, NJ
|
| Public(NYSE:MTNB) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as active bookrunner for Matinas BioPharma Holdings on confidentially marketed follow-on offering | Sole Bookrunner | NYSE:MTNB | 50.0 | Healthcare |
| Equity | 2019-12-17 | 75.0 | | Neoleukin Therapeutics | Seattle, WA
|
| Public (Nasdaq:NLTX) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as active bookrunner for Neuleukin Therapeutics, Inc. on a confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:NLTX | 75.0 | Healthcare |
| Equity | 2019-12-11 | 57.3 | | OrthoPediatrics Corp. | Warsaw, IN
|
| Public (Nasdaq:KIDS) | Equity | Confidentially Marketed Follow-On Offering | Piper Sandler served as active bookrunner for Orthoedicatrics Corp. on a confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:KIDS | 57.3 | Healthcare |
| Equity | 2019-11-13 | 26.0 | | Fulgent Genetics, Inc. | Temple City, CA
|
| Public (Nasdaq:FLGT) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as sole bookrunner for Fulgent Genetics, Inc. on confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:FLGT | 26.0 | Healthcare |
| Equity | 2019-11-07 | 52.0 | | TELA Bio, Inc. | Malvern, PA
|
| Public (Nasdaq:TELA) | Equity | Initial Public Offering | Piper Jaffray served as active bookrunner for TELA Bio, Inc. on initial public offering | Joint Bookrunner | Nasdaq:TELA | 52.0 | Healthcare |
| Equity | 2019-11-06 | 100.0 | | Arvinas, Inc. | New Haven, CT
|
| Public (Nasdaq:ARVN) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as active bookrunner for Arvinas, Inc. on confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:ARVN | 100.0 | Healthcare |
| Equity | 2019-10-30 | 92.0 | | Oyster Point Pharma, Inc. | Princeton, NJ
|
| Public (Nasdaq:OYST) | Equity | Initial Public Offering | Piper Jaffray served as joint bookrunner for Oyster Point Pharma, Inc. on its initial public offering
| Joint Bookrunner | Nasdaq:OYST | 92.0 | Healthcare |
| Equity | 2019-10-24 | 130.0 | | Progyny, Inc. | New York, NY
|
| Public (Nasdaq:PGNY) | Equity | Initial Public Offering | Piper Jaffray served as passive bookrunner for Progyny, Inc. on initial public offering | Co-Manager | Nasdaq:PGNY | 130.0 | Healthcare |
| Equity | 2019-10-16 | 230.0 | | Natera, Inc. | San Carlos, CA
|
| Public (Nasdaq:NTRA) | Equity | Follow-On Offering | Piper Jaffray served as active bookrunner for Natera, Inc. on October 2019 follow-on offering | Joint Bookrunner | Nasdaq:NTRA | 230.0 | Healthcare |
| Equity | 2019-09-17 | 175.0 | | IGM Biosciences, Inc. | Mountain View, CA
|
| Public (Nasdaq:IGMS) | Equity | Initial Public Offering | Piper Jaffray served as active bookrunner for IGM Biosciences, Inc. on September 2019 initial public offering | Sole Bookrunner | Nasdaq:IGMS | 175.0 | Healthcare |
| Equity | 2019-09-17 | 86.1 | | PDL BioPharma, Inc. | Incline Village, NV
|
| Public (Nasdaq:PDLI) | Equity | Convertible | Piper Jaffray served as financial advisor for PDL BioPharma, Inc. on September 2019 private convertible exchange | Sole Bookrunner | Nasdaq:PDLI | 86.1 | Healthcare |
| Equity | 2019-09-12 | 86.3 | | Heska Corporation | Loveland, CO
|
| Public (Nasdaq:HSKA) | Equity | Convertible | Piper Jaffray served as active bookrunner for Heska Corporation on September 2019 convertible debt offering | Joint Bookrunner | Nasdaq:HSKA | 86.3 | Healthcare |
| Equity | 2019-08-14 | 400.0 | | Deciphera Pharmaceuticals, Inc. | Waltham, MA
|
| Public (Nasdaq:DCPH) | Equity | Follow-On Offering | Piper Jaffray served as active bookrunner for Deciphera Pharmaceuticals, Inc. on August 2019 follow-on offering | Lead Bookrunner | Nasdaq:DCPH | 400.0 | Healthcare |
| Equity | 2019-08-07 | 75.2 | | MeiraGTx Holdings plc | New York, NY
|
| Public (Nasdaq:MGTX) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as active bookrunner for MeiraGTx Holdings plc on August 2019 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:MGTX | 75.2 | Healthcare |
| Equity | 2019-07-31 | 57.7 | | Alphatec Holdings, Inc. | Carlsbad, CA
|
| Public (Nasdaq:ATEC) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as active bookrunner for Alphatec Holdings, Inc. on July 2019 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:ATEC | 57.7 | Healthcare |
| Equity | 2019-07-26 | 55.0 | Chiasma, Inc. | Public (Nasdaq:CHIM) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as active bookrunner for Chiasma, Inc. on July 2019 confidentially marked follow-on offering | Lead Bookrunner | Nasdaq:CHMA | 55.0 | Healthcare |
| Equity | 2019-07-24 | 126.5 | | Cara Therapeutics Inc. | Shelton, CT
|
| Public (Nasdaq:CARA) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as passive bookrunner for Cara Therapeutics, Inc. on July 2019 confidentially marked follow-on offering | Passive Bookrunner | Nasdaq:CARA | 126.5 | Healthcare |
| Equity | 2019-07-24 | 209.3 | | Health Catalyst, LLC | Salt Lake City, UT
|
| Public (Nasdaq:HCAT) | Equity | Initial Public Offering | Piper Jaffray served as passive bookrunner for Health Catalyst, Inc. on July 2019 initial public offering | Co-Manager | Nasdaq:HCAT | 209.3 | Healthcare |
| Equity | 2019-07-24 | 408.5 | | Livongo Health Inc. | Palo Alto, CA
|
| Public (Nasdaq:LVGO) | Equity | Initial Public Offering | Piper Jaffray served as co-manager for Livongo Health, Inc. on July 2019 initial public offering | Co-Manager | Nasdaq:LVGO | 408.5 | Healthcare |
| Equity | 2019-07-17 | 167.4 | | Phreesia Inc. | New York, NY
|
| LLR Partners Inc. | Equity | Initial Public Offering | Piper Jaffray served as passive bookrunner for Phreesia, Inc. on July 2019 initial public offering | Passive Bookrunner | TSE:PHR | 167.4 | Healthcare |
| Equity | 2019-06-27 | 400.8 | | BridgeBio Pharma LLC | Palo Alto, CA
|
| Public (Nasdaq:BBIO) | Equity | Initial Public Offering | Piper Jaffray served as passive bookrunner for BridgeBio Pharma, Inc. on June 2019 initial public offering | Passive Bookrunner | Nasdaq:BBIO | 400.8 | Healthcare |
| Equity | 2019-06-27 | 640.7 | | Change Healthcare Corporation | Brentwood, TN
|
| Public (Nasdaq:CHNG) | Equity | Initial Public Offering | Piper Jaffray served as co-manager for Change Healthcare Inc. on June 2019 initial public offering | Co-Manager | Nasdaq:CHNG | 640.7 | Healthcare |
| Equity | 2019-06-26 | 0 | | Change Healthcare Corporation | Brentwood, TN
|
| Public (Nasdaq:CHNG) | Equity | Convertible | Piper Jaffray served as co-manager for Change Healthcare on June 2019 convertible offering | Co-Manager | Nasdaq:CHNG | Undisclosed | Healthcare |
| Equity | 2019-06-26 | 20.0 | | MOTUS GI Medical Technologies Ltd. | Tirat Carmel,
|
| Public (Nasdaq:MOTS) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for Motus GI Holdings, Inc. on June 2019 confidentially marketed follow-on offering | Sole Bookrunner | Nasdaq:MOTS | 20.0 | Healthcare |
| Equity | 2019-06-20 | 34.5 | | Eloxx Pharmaceuticals, Inc. | Waltham, MA
|
| Public (Nasdaq:ELOX) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as active bookrunner for Eloxx Pharmaceuticals, Inc. on June 2019 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:ELOX | 34.5 | Healthcare |
| Equity | 2019-06-18 | 300.0 | | Biohaven Pharmaceutical Holding Company Ltd. | New Haven, CT
|
| Public (NYSE:BHVN) | Equity | Follow-On Offering | Piper Jaffray served as active bookrunner for Biohaven Pharmaceutical on June 2019 follow-on offering | Joint Bookrunner | NYSE:BHVN | 300.0 | Healthcare |
| Equity | 2019-06-17 | 17.5 | | Rockwell Medical, Inc. | Wixom, MI
|
| Public (Nasdaq:RMTI) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as active bookrunner for Rockwell Medical, Inc. on June 2019 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:RMTI | 17.5 | Healthcare |
| Equity | 2019-05-31 | 31.2 | | Kiadis Pharma B.V. | Amsterdam,
|
| Public (ENXTAM:KDS) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as joint bookrunner for Kiadis Pharma on May 2019 Reg D/Reg S confidentially marketing follow-on offering
| Joint Bookrunner | ENXTAM:KDS | 31.2 | Healthcare |
| Equity | 2019-05-31 | 40.0 | XBiotech, Inc. | Public (Nasdaq:XBIT) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for XBiotech Inc. on May 2019 confidentially marketed follow-on offering | Sole Bookrunner | Nasdaq:XBIT | 40.0 | Healthcare |
| Equity | 2019-05-22 | 60.7 | | Bicycle Therapeutics Limited | Cambridge, UK
|
| Public (Nasdaq:BCYC) | Equity | Initial Public Offering | Piper Jaffray served as active bookrunner for Bicycle Therapeutics Limited May 2019 initial public offering | Joint Bookrunner | Nasdaq:BCYC | 60.7 | Healthcare |
| Equity | 2019-05-16 | 2898.0 | | Avantor Performance Materials, Inc. | Center Valley, PA
|
| Public (NYSE:AVTR) | Equity | Initial Public Offering | Piper Jaffray served as passive bookrunner for Avantor, Inc. on May 2019 initial public offering | Passive Bookrunner | NYSE:AVTR | 2898.0 | Healthcare |
| Equity | 2019-05-16 | 1035.0 | | Avantor Performance Materials, Inc. | Center Valley, PA
|
| Public (NYSE:AVTR) | Equity | Convertible | Piper Jaffray served as passive bookrunner for Avantor, Inc. on May 2019 Series A mandatory convertible preferred shares offering | Passive Bookrunner | NYSE:AVTR | 1035.0 | Healthcare |
| Equity | 2019-05-08 | 82.5 | | Milestone Pharmaceuticals Inc. | Saint-Laurent, QC
|
| Public (Nasdaq:MIST) | Equity | Initial Public Offering | Piper Jaffray served as bookrunner for Milestone Pharmaceuticals Inc. on May 2019 initial public offering | Joint Bookrunner | Nasdaq:MIST | 82.5 | Healthcare |
| Equity | 2019-05-08 | 86.3 | | NextCure, Inc. | Beltsville, MD
|
| Public (Nasdaq:NXTC) | Equity | Initial Public Offering | Piper Jaffray served as active bookrunner for NextCure, Inc. on May 2019 initial public offering | Lead Bookrunner | Nasdaq:NXTC | 86.3 | Healthcare |
| Equity | 2019-04-17 | 100.0 | | Natera, Inc. | San Carlos, CA
|
| Public (Nasdaq:NTRA) | Equity | Follow-On Offering | Piper Jaffray served as joint bookrunner for Natera, Inc. on April 2019 follow-on offering | Joint Bookrunner | Nasdaq:NTRA | 100.0 | Healthcare |
| Equity | 2019-04-05 | 65.0 | | Syros Pharmaceuticals, Inc. | Cambridge, MA
|
| Public (Nasdaq:SYRS) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as joint bookrunner for Syros Pharmaceuticals, Inc. on April 2019 confidentially marketed follow-on offering | Joint Bookrunner | Nasdaq:SYRS | 65.0 | Healthcare |
| Equity | 2019-03-07 | 22.0 | | Aptevo Therapeutics Inc. | Seattle, WA
|
| Public (Nasdaq:APVO) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as sole bookrunner for Aptevo Therapeutics Inc. on March 2019 confidentially marketed follow-on offering | Sole Bookrunner | APVO | 22.0 | Healthcare |
| Equity | 2019-03-05 | 275.3 | | Benefitfocus, Inc. | Charleston, SC
|
| Public (Nasdaq:BNFT) | Equity | Follow-On Offering | Piper Jaffray served as co-manager for Benefitfocus, Inc on February 2019 follow-on offering | Co-Manager | BNFT | 275.3 | Healthcare |
| Equity | 2019-02-13 | 78.5 | | Inovio Pharmaceuticals, Inc. | Plymouth Meeting, PA
|
| Public (Nasdaq:INO) | Equity | Convertible | Piper Jaffray served as lead bookrunner for Inovio Pharmaceuticals, Inc. on February 2019 convertible debt offering | Lead Bookrunner | Nasdaq:INO | 78.5 | Healthcare |
| Equity | 2019-02-07 | 325.0 | | Tabula Rasa Healthcare, Inc. | Moorestown, NJ
|
| Public (Nasdaq:TRHC) | Equity | Convertible | Piper Jaffray served as co-manager for Tabula Rasa HealthCare, Inc. on February 2019 convertible debt offering | Co-Manager | Nasdaq:TRHC | 325.0 | Healthcare |
| Equity | 2019-02-07 | 35.0 | | OncoCyte Corporation | Alameda, CA
|
| Public (NYSE:OCX) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for OncoCyte Corporation on February 2019 confidentially marketed follow-on offering | Lead Bookrunner | NYSE:OCX | 35.0 | Healthcare |
| Equity | 2019-01-16 | 25.3 | | Alpine Immune Sciences, Inc. | Seattle, WA
|
| Public (Nasdaq:ALPN) | Equity | PIPE | Piper Jaffray served as sole bookrunner for Alpine Immune Sciences, Inc. on January 2019 PIPE offering | Sole Bookrunner | Nasdaq:ALPN | 25.3 | Healthcare |
| Equity | 2019-01-16 | 115.0 | | Revance Therapeutics, Inc. | Newark, CA
|
| Public (Nasdaq:RVNC) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for Revance Therapeutics, Inc. on January 2018 follow-on offering | Sole Bookrunner | Nasdaq:RVNC | 115.0 | Healthcare |
| Equity | 2018-12-19 | 13.5 | | MOTUS GI Medical Technologies Ltd. | Tirat Carmel,
|
| Public (Nasdaq:MOTS) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for Motus GI Holdings, Inc. on December 2018 follow-on offering | Sole Bookrunner | Nasdaq:MOTS | 13.5 | Healthcare |
| Equity | 2018-12-12 | 125.0 | | Biohaven Pharmaceutical Holding Company Ltd. | New Haven, CT
|
| Public (NYSE:BHVN) | Equity | Follow-On Offering | Piper Jaffray served as joint bookrunner for Biohaven Pharmaceutical Holding Company Ltd. on December 2018 follow-on offering | Joint Bookrunner | NYSE:BHVN | 125.0 | Healthcare |
| Equity | 2018-12-11 | 63.3 | | Fluidigm Corporation | South San Francisco, CA
|
| Public (Nasdaq:FLDM) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as lead bookrunner for Fluidigm Corporation on December 2018 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:FLDM | 63.3 | Healthcare |
| Equity | 2018-12-07 | 604.4 | | Moderna Therapeutics, Inc. | ,
|
| Private | Equity | Initial Public Offering | Piper Jaffray served as passive bookrunner on December 2018 initial public offering | Passive Bookrunner | | 604.4 | Healthcare |
| Equity | 2018-12-07 | 40.5 | | OrthoPediatrics Corp. | Warsaw, IN
|
| Public (Nasdaq:KIDS) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for OrthoPediatrics Corp. on December 2018 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:KIDS | 40.5 | Healthcare |
| Equity | 2018-11-13 | 56.4 | CareDx, Inc | Public (Nasdaq:CDNA) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for CareDx, Inc. on November 2018 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:CDNA | 56.4 | Healthcare |
| Equity | 2018-10-23 | 74.3 | | Proteostasis Therapeutics, Inc. | Cambridge, MA
|
| Public (Nasdaq:PTI) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for Proteostasis Therapeutics, Inc. on October 2018 follow-on offering | Sole Bookrunner | Nasdaq:PTI | 74.3 | Healthcare |
| Equity | 2018-10-17 | 70.0 | TapImmune, Inc. | Public (Nasdaq:MRKR) | Equity | PIPE | Piper Jaffray served as sole bookrunner for TapImmune, Inc. on June 2018 PIPE | Sole Bookrunner | Nasdaq:MRKR | 70.0 | Healthcare |
| Equity | 2018-10-11 | 57.9 | | SeaSpine Holdings Corporation | Carlsbad, CA
|
| Public (Nasdaq:SPNE) | Equity | Confidentially Marketed Follow-On Offering | Piper Jaffray served as joint bookrunner for SeaSpine Holdings Corporation on October 2018 confidentially marketed follow-on | Joint Bookrunner | Nasdaq:SPNE | 57.9 | Healthcare |
| Equity | 2018-10-04 | 76.9 | | AtriCure, Inc. | West Chester, OH
|
| Public (Nasdaq:ATRC) | Equity | Follow-On Offering | Piper Jaffray served as co-manager for AtriCure, Inc. on October 2018 follow-on offering | Co-Manager | Nasdaq:ATRC | 76.9 | Healthcare |
| Equity | 2018-09-26 | 120.0 | Arvinas | Public (Nasdaq:ARVN) | Equity | Initial Public Offering | Piper Jaffray served as sole bookrunner for Arvinas Holding Company, LLC on September 2018 initial public offering | Sole Bookrunner | Nasdaq:ARVN | 120.0 | Healthcare |
| Equity | 2018-09-26 | 85.0 | | Sutro Biopharma, Inc. | South San Francisco, CA
|
| Public (Nasdaq:STRO) | Equity | Initial Public Offering | Piper Jaffray served as joint bookrunner for Sutro Biopharma Inc. on September 2018 initial public offering | Joint Bookrunner | Nasdaq:STRO | 85.0 | Healthcare |
| Equity | 2018-09-26 | 76.3 | | Ra Medical Systems Inc. | Carlsbad, CA
|
| Public (NYSE:RMED) | Equity | Initial Public Offering | Piper Jaffray served as sole bookrunner for Ra Medical Systems, Inc. on September 2018 initial public offering | Sole Bookrunner | NYSE:RMED | 76.3 | Healthcare |
| Equity | 2018-09-20 | 200.0 | | CRISPR Therapeutics AG | Basel, Basel-Stadt
|
| Public (Nasdaq:CRSP) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for CRISPR Therapeutics, Inc. on September 2018 follow-on offering | Lead Bookrunner | Nasdaq:CRSP | 200.0 | Healthcare |
| Equity | 2018-09-20 | 143.8 | | Fate Therapeutics, Inc. | San Diego, CA
|
| Public (Nasdaq:FATE) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for Fate Therapeutics, Inc. on September 2018 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:FATE | 143.8 | Healthcare |
| Equity | 2018-09-11 | 69.0 | | Nuvectra Corporation | Plano, Texas
|
| Public (Nasdaq:NVTR) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for Nuvectra Corporation on September 2018 confidentially marketed follow-on offering | Sole Bookrunner | Nasdaq:NVTR | 69.0 | Healthcare |
| Equity | 2018-08-17 | 5.7 | | AVEO Pharmaceuticals, Inc. | Cambridge, MA
|
| Public (Nasdaq:AVEO) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for AVEO Pharmaceuticals, Inc. on August 2018 confidentially marketed follow-on | Lead Bookrunner | Nasdaq:AVEO | 5.7 | Healthcare |
| Equity | 2018-08-08 | 37.5 | | Spring Bank Pharmaceuticals, Inc. | Milford, MA
|
| Public (Nasdaq:SBPH) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for Spring Bank Pharmaceuticals, Inc. on August 2018 confidentially marketed follow-on offering | Lead Bookrunner | Nasdaq:SBPH | 37.5 | Healthcare |
| Equity | 2018-07-27 | 10.0 | | ContraFect Corporation | Yonkers, NY
|
| Public (Nasdaq:CFRX) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for Contrafect Corporation on July 2018 confidentially marketed follow-on offering | Sole Bookrunner | Nasdaq:CFRX | 10.0 | Healthcare |
| Equity | 2018-07-25 | 217.4 | | Merit Medical Systems, Inc. | South Jordan, UT
|
| Public (Nasdaq:MMSI) | Equity | Follow-On Offering | Piper Jaffray served as sole bookrunner for Merit Medical Systems, Inc. on July 2018 follow-on offering | Joint Bookrunner | Nasdaq:MMSI | 217.4 | Healthcare |
| Equity | 2018-07-18 | 98.3 | | Cara Therapeutics Inc. | Shelton, CT
|
| Public (Nasdaq:CARA) | Equity | Follow-On Offering | Piper Jaffray served as lead bookrunner for Cara Therapeutics, Inc. on July 2018 follow-on offering | Lead Bookrunner | Nasdaq:CARA | 98.3 | Healthcare |
| Equity | 2018-07-17 | 117.3 | | Crinetics Pharmaceuticals, Inc. | San Diego, CA
|
| Public (Nasdaq:CRNX) | Equity | Initial Public Offering | Piper Jaffray served as lead bookrunner for Crinetics Pharmaceuticals, Inc. on July 2018 IPO | Lead Bookrunner | Nasdaq:CRNX | 117.3 | Healthcare |
| Equity | 2018-06-28 | 93.5 | | Neuronetics, Inc. | Malvern, PA
|
| Public (Nasdaq:STIM) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:STIM | 93.5 | Healthcare |
| Equity | 2018-06-28 | 60.0 | | ZafGen, Inc. | Cambridge, MA
|
| Public (Nasdaq:ZFGN) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ZFGN | 60.0 | Healthcare |
| Equity | 2018-06-06 | 172.0 | | Deciphera Pharmaceuticals, LLC | Lawrence, KS
|
| Public (Nasdaq:DCPH) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:DCPH | 172.0 | Healthcare |
| Equity | 2018-06-06 | 111.3 | OptiNose AS | Public (Nasdaq:OPTN) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:OPTN | 111.3 | Healthcare |
| Equity | 2018-05-29 | 40.0 | | Eiger BioPharmaceuticals, Inc. | Palo Alto, CA
|
| Public (Nasdaq:EIGR) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:EIGR | 40.0 | Healthcare |
| Equity | 2018-05-14 | 125.0 | | Vocera Communications, Inc. | San Jose, CA
|
| Public (NYSE:VCRA) | Equity | Convertible | | Joint Bookrunner | NYSE:VCRA | 125.0 | Healthcare |
| Equity | 2018-05-04 | 42.2 | | ASLAN Pharmaceuticals Pte. Ltd. | Singapore,
|
| Public (Nasdaq:ASLN) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:ASLN | 42.2 | Healthcare |
| Equity | 2018-05-03 | 250.0 | Teladoc, Inc. | Public (NYSE:TDOC) | Equity | Convertible | | Sole Bookrunner | NYSE:TDOC | 250.0 | Healthcare |
| Equity | 2018-04-25 | 57.5 | | Eloxx Pharmaceuticals, Inc. | Waltham, MA
|
| Public (Nasdaq:ELOX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ELOX | 57.5 | Healthcare |
| Equity | 2018-04-19 | 62.4 | | Rigel Pharmaceuticals, Inc. | South San Francisco, CA
|
| Public (Nasdaq:RIGL) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:RIGL | 62.4 | Healthcare |
| Equity | 2018-04-13 | 15.0 | | Vermillion, Inc. | Austin, TX
|
| Public (Nasdaq:VRML) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:VRML | 15.0 | Healthcare |
| Equity | 2018-04-11 | 57.5 | | Novavax, Inc. | Gaithersburg, MD
|
| Public (Nasdaq:NVAX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:NVAX | 57.5 | Healthcare |
| Equity | 2018-03-22 | 8.5 | | Novus Therapeutics, Inc. | Irvine, CA
|
| Public (Nasdaq:NVUS) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:NVUS | 8.5 | Healthcare |
| Equity | 2018-03-20 | 226.3 | Xencor, Inc. | Public (Nasdaq:XNCR) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:XNCR | 226.3 | Healthcare |
| Equity | 2018-02-21 | 202.4 | | Aimmune Therapeutics, Inc. | Brisbane, CA
|
| Public (Nasdaq:AIMT) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:AIMT | 202.4 | Healthcare |
| Equity | 2018-02-14 | 17.5 | | MOTUS GI Medical Technologies Ltd. | Tirat Carmel,
|
| Public (Nasdaq:MOTS) | Equity | Initial Public Offering | | Sole Bookrunner | Nasdaq:MOTS | 17.5 | Healthcare |
| Equity | 2018-02-08 | 60.0 | | Adverum Biotechnologies, Inc. | Menlo Park, CA
|
| Public (Nasdaq:ADVM) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ADVM | 60.0 | Healthcare |
| Equity | 2018-02-08 | 22.0 | | Gemphire Therapeutics Inc. | Northville, MI
|
| Public (Nasdaq:GEMP) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:GEMP | 22.0 | Healthcare |
| Equity | 2018-02-01 | 26.0 | | Nuvectra Corporation | Plano, TX
|
| Public (Nasdaq:NVTR) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:NVTR | 26.0 | Healthcare |
| Equity | 2018-02-01 | 23.0 | | OncoSec Medical Incorporated | ,
|
| Public (Nasdaq:ONCS) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:ONCS | 23.0 | Healthcare |
| Equity | 2018-01-31 | 46.0 | | Syros Pharmaceuticals, Inc. | Cambridge, MA
|
| Public (Nasdaq:SYRS) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:SYRS | 46.0 | Healthcare |
| Equity | 2018-01-25 | 136.9 | | Menlo Therapeutics Inc. | Menlo Park, CA
|
| Public (Nasdaq:MNLO) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:MNLO | 136.9 | Healthcare |
| Equity | 2018-01-25 | 37.4 | | Ocular Therapeutix, Inc. | Bedford, MA
|
| Public (Nasdaq:OCUL) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:OCUL | 37.4 | Healthcare |
| Equity | 2018-01-24 | 57.5 | | Synlogic, Inc. | Cambridge, MA
|
| Public (Nasdaq:SYBX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:SYBX | 57.5 | Healthcare |
| Equity | 2018-01-05 | 38.0 | | Novan, Inc. | Morrisville, NC
|
| Public (Nasdaq:NOVN) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:NOVN | 38.0 | Healthcare |
| Equity | 2018-01-04 | 130.8 | | CRISPR Therapeutics AG | Basel,
|
| Public (Nasdaq:CRSP) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:CRSP | 130.8 | Healthcare |
| Equity | 2017-12-13 | 265.5 | | arGEN-X N.V | Breda, North Brabant,
|
| Public (Nasdaq:ARGX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ARGX | 265.5 | Healthcare |
| Equity | 2017-12-13 | 46.0 | | Fate Therapeutics, Inc. | San Diego, CA
|
| Public (Nasdaq:FATE) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:FATE | 46.0 | Healthcare |
| Equity | 2017-12-12 | 15.0 | | Soleno Therapeutics, Inc. | Redwood City, CA
|
| Public (Nasdaq:SLNO) | Equity | PIPE | | Sole Bookrunner | Nasdaq:SLNO | 15.0 | Healthcare |
| Equity | 2017-12-08 | 94.9 | | Tabula Rasa Healthcare, Inc. | Moorestown, NJ
|
| Public (Nasdaq:TRHC) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:TRHC | 94.9 | Healthcare |
| Equity | 2017-11-29 | 172.4 | Teladoc, Inc. | Public (NYSE:TDOC) | Equity | Follow-On Offering | | Joint Bookrunner | NYSE:TDOC | 172.4 | Healthcare |
| Equity | 2017-11-28 | 57.5 | | Catalyst Pharmaceuticals, Inc. | Coral Gables, FL
|
| Public (Nasdaq:CPRX) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:CPRX | 57.5 | Healthcare |
| Equity | 2017-11-16 | 18.8 | | Vascular Biogenics Ltd. | Or Yehuda,
|
| Public (Nasdaq:VBLT) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:VBLT | 18.8 | Healthcare |
| Equity | 2017-11-13 | 805.0 | | Alnylam Pharmaceuticals, Inc. | Cambridge, MA
|
| Public (Nasdaq:ALNY) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:ALNY | 805.0 | Healthcare |
| Equity | 2017-10-24 | 15.0 | | Anthera Pharmaceuticals, Inc. | Hayward, CA
|
| Public (Nasdaq:ANTH) | Equity | PIPE | | Sole Bookrunner | Nasdaq:ANTH | 15.0 | Healthcare |
| Equity | 2017-10-16 | 138.0 | | OptiNose AS | Yardly, PA
OptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. |
| Public (Nasdaq:OPTN) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:OPTN | 138.0 | Healthcare |
| Equity | 2017-10-12 | 59.8 | | OrthoPediatrics Corp. | Warsaw, IN
OrthoPediatrics is the only medical device company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. |
| Public (Nasdaq:KIDS) | Equity | Initial Public Offering | | Lead Bookrunner | Nasdaq:KIDS | 59.8 | Healthcare |
| Equity | 2017-09-27 | 138.8 | | Deciphera Pharmaceuticals, LLC | Lawrence, KS
|
| Public (Nasdaq:DCPH) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:DCPH | 138.8 | Healthcare |
| Equity | 2017-09-26 | 80.3 | | Kadmon Holdings, LLC | New York, NY
|
| Public (Nasdaq:KDMN) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:KDMN | 80.3 | Healthcare |
| Equity | 2017-09-17 | 258.8 | | Array BioPharma Inc. | Boulder, CO
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat patients afflicted with cancer. |
| Public (Nasdaq:ARRY) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:ARRY | 258.8 | Healthcare |
| Equity | 2017-09-15 | 125.2 | | Tactile Systems Technology, Inc. | Minneapolis, MN
|
| Public (Nasdaq:TCMD) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:TCMD | 125.2 | Healthcare |
| Equity | 2017-08-28 | 45.8 | | aTyr Pharma Inc. | San Diego, CA
|
| Public (Nasdaq:LIFE) | Equity | PIPE | | Lead Bookrunner | Nasdaq:LIFE | 45.8 | Healthcare |
| Equity | 2017-08-17 | 14.7 | | Altimmune, Inc. | Gaithersburg, MD
|
| Public (Nasdaq:ALT) | Equity | URD / RD | | Sole Bookrunner | Nasdaq:ALT | 14.7 | Healthcare |
| Equity | 2017-07-28 | 65.0 | | Tetraphase Pharmaceuticals, Inc. | Watertown, MA
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. The company was founded in 2006 and is headquartered in Watertown, MA. |
| Public (Nasdaq:TTPH) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:TTPH | 65.0 | Healthcare |
| Equity | 2017-07-20 | 40.0 | | ContraFect Corporation | Yonkers, NY
ContraFect Corp. is a clinical-stage biotechnology company. It focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens, p |
| Public (Nasdaq:CFRX) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:CFRX | 40.0 | Healthcare |
| Equity | 2017-07-19 | 75.0 | | Inovio Pharmaceuticals, Inc. | Plymouth Meeting, PA
Inovio Pharmaceuticals, Inc. is a bio pharmaceutical company. It develops active DNA immunotherapies for cancer and infectious diseases. The company was founded in 1983 and is headquartered in Plymouth Meeting, PA. |
| Public (Nasdaq:INO) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:INO | 75.0 | Healthcare |
| Equity | 2017-07-18 | 97.2 | | Cymabay Therapeutics, Inc. | Newark, CA
CymaBay Therapeutics, Inc. is a clinical stage company, which engages in the research and development of biopharmaceutical products. The company was founded in 1988 and is headquartered in Newark, CA. |
| Public (Nasdaq:CBAY) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:CBAY | 97.2 | Healthcare |
| Equity | 2017-05-17 | 60.0 | | arGEN-X N.V. | Breda, NET
A clinical-stage biopharmaceutical company that focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. |
| Public (SE:ARGX) | Equity | Initial Public Offering | | Joint Bookrunner | SE:ARGX | 60.0 | Healthcare |
| Equity | 2017-05-10 | 79.3 | | Accelerate Diagnostics, Inc. | Tucson, AZ
An in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. |
| Public (Nasdaq:AXDX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:AXDX | 79.3 | Healthcare |
| Equity | 2017-05-03 | 76.9 | | Ignyta, Inc. | San Diego, CA
Biotechnology company focused on precision medicine in oncology. |
| Public (Nasdaq:RXDX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:RXDX | 76.9 | Healthcare |
| Equity | 2017-05-03 | 168.3 | | Biohaven Pharmaceutical Holding Company Limited | New Haven , CT
Clinical-stage biopharmaceutical company with a portfolio of innovative,
late-stage product candidates targeting neurological diseases, including rare disorders. |
| Public (NYSE:BHVN) | Equity | Initial Public Offering | | Joint Bookrunner | NYSE:BHVN | 168.3 | Healthcare |
| Equity | 2017-04-19 | 74.5 | | Audentes Therapeutics, Inc. | San Francisco, CA
A biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. |
| Public (Nasdaq:BOLD) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:BOLD | 74.5 | Healthcare |
| Equity | 2017-03-22 | 127.1 | | Merit Medical Systems, Inc. | South Jordan, UT
Manufactures and markets products used in diagnostic and interventional cardiology and radiology procedures. |
| Public (Nasda:MMSI) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq: MMSI | 127.1 | Healthcare |
| Equity | 2017-03-22 | 75.8 | | Regenxbio Inc. | Rockville, MD
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. |
| Public (Nasdaq:RGNX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:RGNX | 75.8 | Healthcare |
| Equity | 2017-03-22 | 22.5 | | Tandem Diabetes Care, Inc. | San Diego, CA
Produces medical devices and designs, develops, and commercializes products for people with insulin-dependent diabetes. Tandem Diabetes Care offers its products to the medical industry in the United States. |
| Public (Nasdaq:TNDM) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:TNDM | 22.5 | Healthcare |
| Equity | 2017-03-17 | 25.5 | | Zosano Pharma Corporation | Fremont, CA
Clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. |
| Public (Nasdaq:ZSAN) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:ZSAN | 25.5 | Healthcare |
| Equity | 2017-03-10 | 45.0 | | BioCryst Pharmaceutricals, Inc. | Durham, NC
Designs, optimizes, and develops small-molecule novel pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases, and cancer. |
| Public (Nasdaq:BCRX) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:BCRX | 45.0 | Healthcare |
| Equity | 2017-03-10 | 12.5 | | Gemphire Therapeutics Inc. | Northville, MI
Clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. |
| Public (Nasdaq:GEMP) | Equity | PIPE | | Sole Bookrunner | Nasdaq:GEMP | 12.5 | Healthcare |
| Equity | 2017-03-08 | 22.7 | | Kadmon Holdings, LLC | New York, NY
Kadmon Holdings, LLC, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics to address unmet medical needs. |
| Public (NYSE:KDMN) | Equity | PIPE | | Joint Bookrunner | NYSE:KDMN | 22.7 | Healthcare |
| Equity | 2017-01-27 | 81.6 | | K2M Group Holdings, Inc. | Leesburg, VA
A global medical device company focused on designing, developing and commercializing innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most difficult a |
| Public (Nasdaq:KTWO) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:KTWO | 81.6 | Healthcare |
| Equity | 2017-01-25 | 60.0 | | Entellus Medical, Inc. | Plymouth, MN
Medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. |
| Public (Nasdaq:ENTL) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ENTL | 60.0 | Healthcare |
| Equity | 2017-01-18 | 50.4 | | Zynerba Pharmaceuticals, Inc. | Devon, PA
A specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. |
| Public (Nasdaq:ZYNE) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ZYNE | 50.4 | Healthcare |
| Equity | 2017-01-18 | 138.2 | | Teladoc, Inc. | Dallas, TX
The nation's first and largest telehealth platform, delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone.
|
| Public (NYSE:TDOC) | Equity | Follow-On Offering | | Joint Bookrunner | NYSE:TDOC | 138.2 | Healthcare |
| Equity | 2016-03-24 | 35.0 | | Vitae Pharmaceuticals, Inc. | Fort Washington, PA
Engages in the structure-based discovery and development of molecule compounds for the treatment of chronic kidney disease, diabetes, Alzheimers disease, and atherosclerosis. |
| Public (Nasdaq:VTAE) | Equity | URD / RD | | Lead Bookrunner | Nasdaq:VTAE | 35.0 | Healthcare |
| Equity | 2016-01-26 | 300.0 | | Novavax, Inc. | Gaithersburg, MD
A clinical-stage biopharmaceutical company focused on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. |
| Public (Nasdaq:NVAX) | Equity | Convertible | | Lead Manager | Nasdaq:NVAX | 300.0 | Healthcare |
| Equity | 2016-01-07 | 57.5 | | Adamas Pharmaceuticals Inc. | Emeryville, CA
Focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems |
| Public (Nasdaq:ADMS) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:ADMS | 57.5 | Healthcare |
| Equity | 2016-01-07 | 55.0 | | Collegium Pharmaceuticals Inc. | Canton, MA
Focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. |
| Public (Nasdaq:COLL) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:COLL | 55.0 | Healthcare |
| Equity | 2016-01-06 | 100.0 | | Otonomy, Inc. | San Diego, CA
Focuses on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear. |
| Public (Nasdaq:OTIC) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:OTIC | 100.0 | Healthcare |
| Equity | 2015-12-10 | 95.0 | | Accelerate Diagnostics, Inc. | Tucson, AZ
An in vitro diagnostics company, focuses on developing and commercializing solutions for the diagnosis of serious infections. |
| Public (Nasdaq:AXDX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:AXDX | 95.0 | Healthcare |
| Equity | 2015-12-04 | 55.0 | | CTI BioPharma Corp. | Seattle, WA
Engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers. |
| Public (Nasdaq:CTIC) | Equity | Convertible | | Sole Bookrunner | Nasdaq:CTIC | 55.0 | Healthcare |
| Equity | 2015-12-02 | 440.0 | | AmSurg Corp. | Nashville, TN
Provides ambulatory and physician services. |
| Public (Nasdaq:AMSG) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:AMSG | 440.0 | Healthcare |
| Equity | 2015-11-10 | 70.0 | | Voyager Therapeutics, Inc. | Cambridge, MA
Develops life-changing treatments for fatal and debilitating diseases of the central nervous system. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:VYGR | 70.0 | Healthcare |
| Equity | 2015-11-03 | 117.0 | | Revance Therapeutics, Inc. | Newark, CA
Engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. |
| Public (Nasdaq:RVNC) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:RVNC | 117.0 | Healthcare |
| Equity | 2015-11-03 | 0 | | Vascular Biogenics Ltd. | Or Yehuda, Israel,
Focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. |
| Public (Nasdaq:VBLT) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:VBLT | Undisclosed | Healthcare |
| Equity | 2015-10-28 | 110.0 | | Endologix, Inc. | Irvine, CA
Engages in the development, manufacture, sale, and marketing of minimally invasive therapies for the treatment of vascular diseases. |
| Public (Nasdaq:ELGX) | Equity | Convertible | | Sole Bookrunner | Nasdaq:ELGX | 110.0 | Healthcare |
| Equity | 2015-10-27 | 50.0 | | CTI BioPharma Corp. | Seattle, WA
Engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. |
| Public (Nasdaq:CTIC) | Equity | Convertible | | Sole Bookrunner | Nasdaq:CTIC | 50.0 | Healthcare |
| Equity | 2015-10-01 | 46.0 | | Medgenics, Inc. | Wayne, PA
Engaged in the research and development of products in the field of biotechnology and associated medical equipment in the United States. |
| Public (NYSE:MDGN) | Equity | URD / RD | | Sole Bookrunner | NYSE:MDGN | 46.0 | Healthcare |
| Equity | 2015-09-18 | 66.0 | | Sientra, Inc. | Santa Barbara, CA
Develops and sells medical aesthetics products to plastic surgeons in the United States. |
| Public (Nasdaq:SIEN) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:SIEN | 66.0 | Healthcare |
| Equity | 2015-09-16 | 159.4 | | Regenxbio Inc. | Rockville, MD
Develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:RGNX | 159.4 | Healthcare |
| Equity | 2015-08-27 | 207.2 | | NantKwest, Inc. | Cardiff-by-the-Sea, CA
Develops and commercializes a product pipeline for the treatment of cancers and viral infections. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:NK | 207.2 | Healthcare |
| Equity | 2015-08-13 | 80.0 | | LDR Holding Corporation | Austin, TX
Focuses on designing and commercializing various surgical technologies for the treatment of patients suffering from spine disorders. |
| Public (Nasdaq:LDRH) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:LDRH | 80.0 | Healthcare |
| Equity | 2015-08-12 | 68.8 | | Inotek Pharmaceuticals Corporation | Lexington, MA
Focuses on the discovery, development, and commercialization of therapies for glaucoma. |
| Public (Nasdaq:ITEK) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ITEK | 68.8 | Healthcare |
| Equity | 2015-08-06 | 73.5 | | Benefitfocus, Inc. | Charleston, SC
Provides cloud-based benefits software solutions for consumers, employers, insurance carriers, and brokers under a software-as-a-service model. |
| Public (Nasdaq:BNFT) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:BNFT | 73.5 | Healthcare |
| Equity | 2015-08-05 | 160.0 | | Aimmune Therapeutics, Inc. | Brisbane, CA
Offers oral immunotherapy services for food allergies. |
| Public (Nasdaq:AIMT) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:AIMT | 160.0 | Healthcare |
| Equity | 2015-08-05 | 68.5 | | Imprivata Inc. | Lexington, MA
Provides authentication and access management technology solutions for the healthcare industry. |
| Public (NYSE:IMPR) | Equity | Follow-On Offering | | Joint Bookrunner | NYSE:IMPR | 68.5 | Healthcare |
| Equity | 2015-08-04 | 42.0 | | Zynerba Pharmaceuticals, Inc. | Devon, PA
Develops transdermal cannabinoid treatments for patients. |
| Public (Nasdaq:ZYNE) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:ZYNE | 42.0 | Healthcare |
| Equity | 2015-07-29 | 70.0 | | Cara Therapeutics Inc. | Shelton, CT
Focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. |
| Public (Nasdaq:CARA) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:CARA | 70.0 | Healthcare |
| Equity | 2015-07-29 | 45.0 | | Genocea Biosciences, Inc. | Cambridge, MA
Engages in vaccine discovery and development. |
| Public (Nasdaq:GNCA) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:GNCA | 45.0 | Healthcare |
| Equity | 2015-07-29 | 117.2 | | vTv Therapeutics Inc. | High Point, NC
Focuses on the discovery and development of human therapeutics to fill unmet medical needs. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:VTVT | 117.2 | Healthcare |
| Equity | 2015-07-29 | 357.0 | | Adeptus Health Inc. | Lewisville, TX
Owns and operates a network of independent freestanding emergency rooms in the United States. |
| Public (NYSE:ADPT) | Equity | Follow-On Offering | | Co-Manager | NYSE:ADPT | 357.0 | Healthcare |
| Equity | 2015-07-27 | 207.2 | | NantKwest, Inc. | Cardiff-by-the-Sea, CA
Develops immunotherapeutic agents for various clinical conditions. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:NK | 207.2 | Healthcare |
| Equity | 2015-07-16 | 20.0 | | TrovaGene, Inc. | San Diego, CA
Focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology. |
| Public (Nasdaq:TROV) | Equity | URD / RD | | Sole Bookrunner | Nasdaq:TROV | 20.0 | Healthcare |
| Equity | 2015-07-15 | 20.0 | | Cymabay Therapeutics, Inc. | Newark, CA
Focuses on the discovery and development of various therapies for the treatment of gout and metabolic diseases. |
| Public (Nasdaq:CBAY) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:CBAY | 20.0 | Healthcare |
| Equity | 2015-07-08 | 25.0 | | Anthera Pharmaceuticals, Inc. | Hayward, CA
Focuses on developing and commercializing products to treat diseases associated with inflammation. |
| Public (Nasdaq:ANTH) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:ANTH | 25.0 | Healthcare |
| Equity | 2015-07-01 | 180.0 | | Natera, Inc. | San Carlos, CA
Develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:NTRA | 180.0 | Healthcare |
| Equity | 2015-06-18 | 100.1 | | Celyad SA | Mont-Saint-Guibert, WBR
Develops and commercializes regenerative and protective therapies for cardiovascular diseases in Belgium. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:CYAD | 100.1 | Healthcare |
| Equity | 2015-06-17 | 46.1 | | Organovo Holdings, Inc. | San Diego, CA
Develops and commercializes functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. |
| Public (NYSE:ONVO) | Equity | URD / RD | | Joint Bookrunner | NYSE:ONVO | 46.1 | Healthcare |
| Equity | 2015-06-11 | 55.2 | | Invuity, Inc. | San Francisco, CA
Develops visualization products for the less invasive surgical field applications. |
| Private | Equity | Initial Public Offering | | Lead Bookrunner | Nasdaq:IVTY | 55.2 | Healthcare |
| Equity | 2015-06-10 | 172.6 | | Chimerix, Inc. | Durham, NC
Develops and commercializes oral antivirals to address unmet medical needs in the United States. |
| Public (Nasdaq:CMRX) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:CMRX | 172.6 | Healthcare |
| Equity | 2015-06-10 | 75.0 | | Ignyta, Inc. | San Diego, CA
Develops and commercializing new drugs for cancer patients. |
| Public (Nasdaq:RXDX) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:RXDX | 75.0 | Healthcare |
| Equity | 2015-05-06 | 0 | | Collegium Pharmaceutical, Inc. | Canton, MA
Develops a portfolio of late stage pharmaceutical products for the treatment of chronic pain. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:COLL | Undisclosed | Healthcare |
| Equity | 2015-05-06 | 1594.2 | | IMS Health Holdings, Inc. | Danbury, CT
Provides business intelligence to the pharmaceutical and healthcare industries worldwide. |
| Public (NYSE:IMS) | Equity | Follow-On Offering | | Co-Manager | NYSE:IMS | 1594.2 | Healthcare |
| Equity | 2015-05-05 | 46.0 | | Antares Pharma, Inc. | Ewing, NJ
Developer of needle-free systems for administering injectable drugs. |
| Public (Nasdaq:ATRS) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:ATRS | 46.0 | Healthcare |
| Equity | 2015-05-05 | 55.0 | | CoLucid Pharmaceuticals, Inc. | Burlington, MA
Develops therapies for the treatment of central nervous system disorders. |
| Private | Equity | Initial Public Offering | | Lead Bookrunner | Nasdaq:CLCD | 55.0 | Healthcare |
| Equity | 2015-05-05 | 154.0 | | Adeptus Health Inc. | Lewisville, TX
Operator of a network of independent freestanding emergency rooms. |
| Public (NYSE:ADPT) | Equity | Follow-On Offering | | Co-Manager | NYSE:ADPT | 154.0 | Healthcare |
| Equity | 2015-04-29 | 87.4 | | Inovio Pharmaceuticals, Inc. | Blue Bell, PA
Develops and delivers DNA vaccines with a focus on cancers and infectious diseases. |
| Public (Nasdaq:INO) | Equity | URD / RD | | Lead Bookrunner | Nasdaq:INO | 87.4 | Healthcare |
| Equity | 2015-04-28 | 208.1 | | GW Pharmaceuticals plc | Salisbury, Wiltshire, ENG
Develops and commercializes cannabinoid prescription pharmaceutical products for patients suffering from multiple sclerosis and cancer pain. |
| Public (Nasdaq:GWP) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:GWP | 208.1 | Healthcare |
| Equity | 2015-04-23 | 29.9 | | Innocoll Pharmaceuticals Ltd. | Athlone, WH
Sells and markets Gentamicin surgical implant for the prevention and treatment of post operative infections. |
| Public (Nasdaq:INNL) | Equity | Follow-On Offering | | Sole Bookrunner | Nasdaq:INNL | 29.9 | Healthcare |
| Equity | 2015-04-23 | 40.0 | | Veracyte, Inc. | South San Francisco, CA
Develops molecular tests to improve the diagnostic accuracy of cytology samples. |
| Public (Nasdaq:VCYT) | Equity | PIPE | | Joint Bookrunner | Nasdaq:VCYT | 40.0 | Healthcare |
| Equity | 2015-04-09 | 88.5 | | uniQure N.V. | Amsterdam, North Holland,
Develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. |
| Public (Nasdaq:QURE) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:QURE | 88.5 | Healthcare |
| Equity | 2015-03-25 | 201.3 | | Novavax, Inc. | Gaithersburg, MD
Focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. |
| Public (Nasdaq:NVAX) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:NVAX | 201.3 | Healthcare |
| Equity | 2015-03-24 | 228.3 | | Cellectis S.A. | Paris, France,
Operates as a genome engineering company in France and internationally. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:ALCLS | 228.3 | Healthcare |
| Equity | 2015-03-17 | 28.8 | | Anthera Pharmaceuticals, Inc. | Hayward, CA
Focuses on developing and commercializing products to treat diseases associated with inflammation. |
| Public (Nasdaq: ANTH) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:ANTH | 28.8 | Healthcare |
| Equity | 2015-03-16 | 63.8 | | Eagle Pharmaceuticals Inc. | Woodcliff Lake, NJ
Focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. |
| Public (Nasdaq:EGRX) | Equity | URD / RD | | Lead Bookrunner | Nasdaq:EGRX | 63.8 | Healthcare |
| Equity | 2015-03-11 | 51.8 | | Genocea Biosciences, Inc. | Cambridge, MA
Engages in vaccine discovery and development. |
| Public (Nasdaq:GNCA) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:GNCA | 51.8 | Healthcare |
| Equity | 2015-03-03 | 804.0 | | Catalent, Inc. | Somerset, NJ
Provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. |
| Public (NYSE:CTLT) | Equity | Follow-On Offering | | Co-Manager | NYSE:CTLT | 804.0 | Healthcare |
| Equity | 2015-02-26 | 69.4 | | Tandem Diabetes Care, Inc. | San Diego, CA
Focuses on the design, development, and commercialization of various products for people with insulin-dependent diabetes in the United States. |
| Public (Nasdaq:TNDM) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:TNDM | 69.4 | Healthcare |
| Equity | 2015-02-25 | 73.6 | | Lion Biotechnologies, Inc. | Woodland Hills, CA
Develops T-cells and engineered T-cells for the treatment of various cancers. |
| Public (Nasdaq:LBIO) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:LBIO | 73.6 | Healthcare |
| Equity | 2015-02-17 | 41.8 | | Inotek Pharmaceuticals Corporation | Lexington, MA
Develops drug candidates to address significant diseases of the eye. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:ITEK | 41.8 | Healthcare |
| Equity | 2015-02-17 | 21.0 | | Inotek Pharmaceuticals Corporation | Lexington, MA
Develops drug candidates to address significant diseases of the eye. |
| Private | Equity | Convertible | | Joint Bookrunner | Nasdaq:ITEK | 21.0 | Healthcare |
| Equity | 2015-02-12 | 86.3 | | Idera Pharmaceuticals, Inc. | Cambridge, MA
Engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. |
| Public (Nasdaq:IDRA) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:IDRA | 86.3 | Healthcare |
| Equity | 2015-02-12 | 684.9 | | Inovalon, Inc | Bowie, MD
Operates as a data analytics technology company that combines analytics with targeted interventions focusing on clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. |
| Private | Equity | Initial Public Offering | | Co-Manager | Nasdaq:INOV | 684.9 | Healthcare |
| Equity | 2015-02-05 | 23.0 | | TrovaGene, Inc. | San Diego, CA
Focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology. |
| Public (Nasdaq:TROV) | Equity | URD / RD | | Lead Bookrunner | Nasdaq:TROV | 23.0 | Healthcare |
| Equity | 2015-02-04 | 41.8 | | Nexvet Biopharma Pty. Ltd. | Melbourne, Victoria,
Develops biological drugs for companion animals, specifically cats, dogs, and horses. |
| Private | Equity | Initial Public Offering | | Lead Manager | Nasdaq:NVET | 41.8 | Healthcare |
| Equity | 2015-02-03 | 37.4 | | Catalyst Pharmaceutical Partners, Inc. | Coral Gables, FL
Operates as development-stage specialty pharmaceutical company. |
| Public (Nasdaq:CPRX) | Equity | URD / RD | | Lead Bookrunner | Nasdaq:CPRX | 37.4 | Healthcare |
| Equity | 2015-02-02 | 130.4 | | K2M Group Holdings, Inc. | Leesburg, VA
Focuses on designing, developing, and commercializing proprietary complex spine technologies and techniques in the United States and internationally. |
| Public (Nasdaq:KTWO) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:KTWO | 130.4 | Healthcare |
| Equity | 2015-01-29 | 47.4 | | Unilife Corporation | York, PA
Designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. |
| Public (ASX:UNS) | Equity | URD / RD | | Joint Bookrunner | ASX:UNS | 47.4 | Healthcare |
| Equity | 2015-01-29 | 87.9 | | Flex Pharma, Inc. | Boston, MA
Develops clinically proven products and treatments for muscle cramps and spasms. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:FLKS | 87.9 | Healthcare |
| Equity | 2015-01-29 | 57.5 | | Oxford Immunotec Global PLC | Oxfordshire, England,
Focuses on the provision of various tests in the field of immunology in the United States, Europe, Japan, and China. |
| Public (Nasdaq:OXFD) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:OXFD | 57.5 | Healthcare |
| Equity | 2015-01-28 | 90.0 | | Entellus Medical, Inc. | Plymouth, MN
Develops and markets device technology and treatment solutions for the needs of ear, nose, and throat patients in the United States. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:ENTL | 90.0 | Healthcare |
| Equity | 2015-01-22 | 85.8 | | Otonomy, Inc. | San Diego, CA
Otonomy, Inc. develops and commercializes therapeutics for the treatment of ear diseases and disorders primarily in the United States. |
| Public (Nasdaq:OTIC) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:OTIC | 85.8 | Healthcare |
| Equity | 2015-01-22 | 41.1 | | Vitae Pharmaceuticals, Inc. | Fort Washington, PA
Engages in the structure-based discovery and development of molecule compounds for the treatment of chronic kidney disease, diabetes, Alzheimers disease, and atherosclerosis. |
| Public (Nasdaq:VTAE) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:VTAE | 41.1 | Healthcare |
| Equity | 2015-01-21 | 202.1 | | The Advisory Board Company | Washington, DC
Engages in the provision of best practices research and analysis. |
| Public (Nasdaq:ABCO) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:ABCO | 202.1 | Healthcare |
| Equity | 2015-01-20 | 517.5 | | Alnylam Pharmaceuticals, Inc. | Cambridge, MA
Develops novel therapeutics based on RNA interference (RNAi). |
| Public (Nasdaq:ALNY) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:ALNY | 517.5 | Healthcare |
| Equity | 2015-01-20 | 105.0 | | Arena Pharmaceuticals, Inc. | San Diego, CA
Develops oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. |
| Public (Nasdaq:ARNA) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:ARNA | 105.0 | Healthcare |
| Equity | 2015-01-08 | 29.9 | | Alcobra Ltd. | Tel Aviv, Isreal,
Focuses on the development and commercialization of proprietary drug candidates. |
| Public (Nasdaq:ADHD) | Equity | URD / RD | | Lead Manager | Nasdaq:ADHD | 29.9 | Healthcare |
| Equity | 2015-01-07 | 162.8 | | Avalanche Biotechnologies, Inc. | Menlo Park, CA
Develops technologies and products for the delivery of therapeutic proteins to the eye to treat wet age-related macular degeneration and other ophthalmologic disorders that include diabetic retinopathy, retinal degeneration, and glaucoma. |
| Public (Nasdaq:AAVL) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:AAVL | 162.8 | Healthcare |
| Equity | 2014-12-23 | 20.0 | | Palatin Technologies Inc. | Cranbury, NJ
Develops peptide therapeutics for the treatment of diseases. |
| Public (Amex:PTN) | Equity | Follow-On Offering | | Sole Bookrunner | Amex:PTN | 20.0 | Healthcare |
| Equity | 2014-12-17 | 160.6 | | Bellicum Pharmaceuticals, Inc. | Houston, TX
Develops novel therapies for the treatment of cancer and other diseases. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:BLCM | 160.6 | Healthcare |
| Equity | 2014-12-02 | 172.5 | | Quidel Corp. | San Diego, CA
Develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women?s health, and gastrointestinal diseases. |
| Public (Nasdaq:QDEL) | Equity | Convertible | | Co-Manager | Nasdaq:QDEL | 172.5 | Healthcare |
| Equity | 2014-11-25 | 13.0 | | Nanobiotix S.A. | Paris, France,
Engages in the development of tools for the treatment of cancer. |
| Public (Enxtpa:NANO) | Equity | PIPE | | Sole Bookrunner | Enxtpa:NANO | 13.0 | Healthcare |
| Equity | 2014-11-24 | 24.2 | | Medgenics, Inc. | Wayne, PA
Engaged in the research and development of products in the field of biotechnology and associated medical equipment. |
| Public (Amex:MDGN) | Equity | URD / RD | | Sole Bookrunner | Amex:MDGN | 24.2 | Healthcare |
| Equity | 2014-11-19 | 65.1 | | Neothetics, Inc. | San Diego, CA
Develops pharmaceutical and biomedical products that address medical and lifestyle indications in ophthalmology and aesthetic medicine. |
| Private | Equity | Initial Public Offering | | Lead Bookrunner | Nasdaq:NEOT | 65.1 | Healthcare |
| Equity | 2014-11-07 | 35.0 | | CTI BioPharma Corp. | Seattle, WA
Engaged in the acquisition, development, and commercialization of treatments for cancer. |
| Public (Nasdaq:CTIC) | Equity | Convertible | | Sole Bookrunner | Nasdaq:CTIC | 35.0 | Healthcare |
| Equity | 2014-10-30 | 121.7 | | Chimerix, Inc. | Durham, NC
Discovers, develops, and commercializes orally available antiviral therapeutics for viral diseases. |
| Public (Nasdaq:CMRX) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:CMRX | 121.7 | Healthcare |
| Equity | 2014-10-29 | 86.2 | | Sientra, Inc. | Santa Barbara, CA
An aesthetics/medical device company that focuses on the aesthetic and plastic surgery markets in North America. |
| Private | Equity | Initial Public Offering | | Lead Bookrunner | Nasdaq:SIEN | 86.2 | Healthcare |
| Equity | 2014-10-29 | 66.7 | | Vanda Pharmaceuticals, Inc. | Washington, DC
Develops and commercializes pharmaceutical products. |
| Public (Nasdaq:VNDA) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:VNDA | 66.7 | Healthcare |
| Equity | 2014-09-23 | 230.2 | | Avanir Pharmaceuticals, Inc. | Aliso Viejo, CA
Aacquires, develops, and commercializes novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. |
| Public (Nasdaq:AVNR) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:AVNR | 230.2 | Healthcare |
| Equity | 2014-08-12 | 115.1 | | Insmed Incorporated | Monmouth Junction, NJ
Operates as a biopharmaceutical company. |
| Public (Nasdaq:INSM) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:INSM | 115.1 | Healthcare |
| Equity | 2014-08-12 | 115.0 | | Otonomy, Inc. | San Diego, CA
A clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of diseases and disorders of the ear. |
| Private | Equity | Initial Public Offering | | Lead Manager | Nasdaq:OTIC | 115.0 | Healthcare |
| Equity | 2014-07-30 | 117.3 | | Avalanche Biotechnologies, Inc. | San Francisco, CA
Clinical-stage biotechnology company that develops technologies and products for the delivery of therapeutic proteins to the eye to treat wet age-related macular degeneration. |
| Public (Nasdaq:AAVL) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:AAVL | 117.3 | Healthcare |
| Equity | 2014-07-30 | 871.3 | | Catalent, Inc. | Somerset, NJ
Contract manufacturer and service provider for the pharmaceutical industry. |
| Public (NYSE:CTLT) | Equity | Initial Public Offering | | Co-Manager | NYSE:CTLT | 871.3 | Healthcare |
| Equity | 2014-07-24 | 58.5 | | Innocoll AG | Athlone, Westmeath,
Global, commercial stage specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:INNL | 58.5 | Healthcare |
| Equity | 2014-07-23 | 63.3 | | Intersect ENT | Palo Alto, CA
Medical device company, engages in developing therapies for ear, nose, and throat physicians in the United States. |
| Public (Nasdaq:XENT) | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:XENT | 63.3 | Healthcare |
| Equity | 2014-07-16 | 109.9 | | Benefitfocus.com | Charleston, SC
Leading provider of cloud-based benefits software solutions for consumers, employers, insurance carriers and brokers. |
| Public (Nasdaq:BNFT) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:BNFT | 109.9 | Healthcare |
| Equity | 2014-07-16 | 42.2 | | CareDx Inc. | Brisbane, CA
Molecular diagnostics company, focuses on discovering, developing, and commercializing noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. |
| Public (Nasdaq:CDNA) | Equity | Initial Public Offering | | Lead Bookrunner | Nasdaq:CDNA | 42.2 | Healthcare |
| Equity | 2014-07-10 | 1075.3 | | Envision Healthcare Holdings, Inc. | Greenwood Village, CO
Provides healthcare-related services to consumers, hospitals, healthcare systems, health plans, and government entities. |
| Public (NYSE:EVHC) | Equity | Follow-On Offering | | Co-Manager | NYSE:EVHC | 1075.3 | Healthcare |
| Equity | 2014-06-26 | 172.5 | | AmSurg Corporation | Nashville, TN
Engages in the development, acquisition, and operation of ambulatory surgery centers (ASC) in partnership with physicians. |
| Public (Nasdaq:AMSG) | Equity | Convertible | | Co-Manager | Nasdaq:AMSG | 172.5 | Healthcare |
| Equity | 2014-06-26 | 439.9 | | AmSurg Corporation | Nashville, TN
Engages in the development, acquisition, and operation of ambulatory surgery centers (ASC) in partnership with physicians. |
| Public (Nasdaq:AMSG) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:AMSG | 439.9 | Healthcare |
| Equity | 2014-06-25 | 56.0 | | Amphastar Pharmaceuticals, Inc. | Rancho Cucamonga, CA
Specialty pharmaceutical company that focuses primarily on developing technically-challenging injectable and inhalation products. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:AMPH | 56.0 | Healthcare |
| Equity | 2014-06-25 | 107.8 | | Adeptus Health Inc. | Lewisville, TX
Operated a network of freestanding emergency rooms. |
| Public (NYSE:ADPT) | Equity | Initial Public Offering | | Co-Manager | NYSE:ADPT | 107.8 | Healthcare |
| Equity | 2014-06-25 | 75.0 | | Imprivata, Inc. | Lexington, MA
Leading provider of authentication and access management technology solutions for the healthcare industry. |
| Public (NYSE:IMPR) | Equity | Initial Public Offering | | Joint Bookrunner | NYSE:IMPR | 75.0 | Healthcare |
| Equity | 2014-06-19 | 147.6 | | GW Pharmaceuticals plc | Salisbury, UK
Biopharmaceutical company focused on discovering and commercializing novel therapeutics from a proprietary cannabinoid product platform. |
| Public (Nasdaq:GWPH) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:GWP | 147.6 | Healthcare |
| Equity | 2014-06-18 | 50.0 | | Parnell Pharmaceuticals Holdings Ltd. | Alexandria, Australia,
Pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:PARN | 50.0 | Healthcare |
| Equity | 2014-06-18 | 122.0 | | Revance Therapeutics, Inc. | Newark, CA
Biopharmaceutical company focused on the development and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. |
| Public (Nasdaq:RVNC) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:RVNC | 122.0 | Healthcare |
| Equity | 2014-06-06 | 100.0 | | Novavax, Inc. | Rockville, MD
Clinical-stage biopharmaceutical company focused on developing recombinant protein nanoparticle vaccines and adjuvants to address infectious diseases worldwide. |
| Public (Nasdaq:NVAX) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:NVAX | 100.0 | Healthcare |
| Equity | 2014-05-29 | 100.0 | | BioCryst Pharmaceuticals, Inc. | Durham, NC
Biotechnology company that designs and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. |
| Public (Nasdaq: BCRX) | Equity | URD / RD | | Lead Manager | Nasdaq:BCRX | 100.0 | Healthcare |
| Equity | 2014-05-28 | 200.0 | | The Spectranetics Corporation | Colorado Springs, CO
Develops single-use medical devices used in minimally invasive procedures within the cardiovascular system. |
| Public (Nasdaq:SPNC) | Equity | Convertible | | Sole Bookrunner | Nasdaq:SPNC | 200.0 | Healthcare |
| Equity | 2014-05-15 | 97.3 | | LDR Holding Corporation | Austin, TX
Global medical device company focused on designing and commercializing surgical technologies for treatment of spine disorders. |
| Public (Nasdaq:LDRH) | Equity | Follow-On Offering | | Lead Bookrunner | Nasdaq:LDRH | 97.3 | Healthcare |
| Equity | 2014-05-07 | 132.0 | | K2M Group Holldings | Leesburg, VA
Global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies and techniques. |
| Public (Nasdaq:KTWO) | Equity | Initial Public Offering | | Lead Bookrunner | Nasdaq:KTWO | 132.0 | Healthcare |
| Equity | 2014-04-09 | 48.0 | | Adamas Pharmaceuticals, Inc. | Emeryville, CA
Specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:ADMS | 48.0 | Healthcare |
| Equity | 2014-04-04 | 1300.0 | | IMS Health Holdings, Inc. | Danbury, CT
Leading global information and technology services company providing clients in the healthcare industry with solutions to measure and improve their performance. |
| Public (NYSE:IMS) | Equity | Initial Public Offering | | Co-Manager | NYSE:IMS | 1300.0 | Healthcare |
| Equity | 2014-04-03 | 25.0 | | Catalyst Pharmaceutical Partners, Inc. | Coral Gables, FL
Development-stage specialty pharmaceutical company focused on novel prescription drugs targeting rare neuromuscular and neurological disorders. |
| Public (Nasdaq:CPRX) | Equity | URD / RD | | Sole Bookrunner | Nasdaq:CPRX | 25.0 | Healthcare |
| Equity | 2014-03-21 | 100.0 | | Sangamo BioSciences, Inc. | Richmond, CA
Clinical stage biopharmaceutical company focused on engineered DNA-binding proteins for the development of therapeutic strategies for unmet medical needs. |
| Public (Nasdaq:SGMO) | Equity | Follow-On Offering | | Co-Lead Manager | Nasdaq:SGMO | 100.0 | Healthcare |
| Equity | 2014-03-12 | 897.0 | | Quintiles Transnational Corp. | Durham, NC
The world?s largest provider of biopharmaceutical development services and commercial outsourcing services. |
| Public (NYSE:Q) | Equity | Follow-On Offering | | Co-Manager | NYSE:Q | 897.0 | Healthcare |
| Equity | 2014-03-11 | 9.9 | | Baxano Surgical, Inc. | Raleigh, NC
Designs, develops, and markets minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. |
| Public (OTCPK:BAXS) | Equity | PIPE | | Joint Bookrunner | OTCPK:BAXS | 9.9 | Healthcare |
| Equity | 2014-02-26 | 63.3 | | Inovio Pharmaceuticals, Inc. | Blue Bell, PA
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. |
| Public (NYSE:INO) | Equity | URD / RD | | Joint Bookrunner | NYSE:INO | 63.3 | Healthcare |
| Equity | 2014-02-19 | 119.9 | | Arrowhead Research Corp. | Pasadena, CA
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. |
| Public (Nasdaq:ARWR) | Equity | URD / RD | | Lead Manager | Nasdaq:ARWR | 119.9 | Healthcare |
| Equity | 2014-02-13 | 94.1 | | AtriCure Inc. | West Chester, OH
AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue. |
| Public (Nasdaq:ATRC) | Equity | URD / RD | | Sole Bookrunner | Nasdaq:ATRC | 94.1 | Healthcare |
| Equity | 2014-02-13 | 60.0 | | BioDelivery Sciences International, Inc. | Raleigh, NC
Develops therapeutics in the areas of pain management and oncology supportive care. |
| Public (Nasdaq:BDSI) | Equity | Block Trade | | Joint Bookrunner | Nasdaq:BDSI | 60.0 | Healthcare |
| Equity | 2014-02-11 | 51.8 | | Eagle Pharmaceuticals Inc. | Woodcliff Lake, NJ
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:EGRX | 51.8 | Healthcare |
| Equity | 2014-02-06 | 49.8 | | Argos Therapeutics, Inc. | Durham, NC
Argos Therapeutics, Inc., a development stage biopharmaceutical company, together with its subsidiaries, develops and commercializes personalized immunotherapies for the treatment of cancer and infectious diseases. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:ARGS | 49.8 | Healthcare |
| Equity | 2014-02-05 | 115.0 | | Halozyme Therapeutics, Inc. | San Diego, CA
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. |
| Public (Nasdaq:HALO) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:HALO | 115.0 | Healthcare |
| Equity | 2014-02-05 | 40.1 | | Idera Pharmaceuticals, Inc. | Cambridge, MA
Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. |
| Public (Nasdaq:IDRA) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:IDRA | 40.1 | Healthcare |
| Equity | 2014-02-05 | 110.4 | | Revance Therapeutics, Inc. | Newark, NJ
Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:RVNC | 110.4 | Healthcare |
| Equity | 2014-02-05 | 964.6 | | Envision Healthcare Holdings, Inc. | Greenwood Village, CO
Envision Healthcare Holdings, Inc. provides healthcare-related services to consumers, hospitals, healthcare systems, health plans, and government entities in the United States. |
| Public (NYSE:EVHC) | Equity | Follow-On Offering | | Co-Manager | NYSE:EVHC | 964.6 | Healthcare |
| Equity | 2014-02-04 | 91.8 | | uniQure B.V. | Amsterdam, North Holland,
Engages in development of human gene based therapies for hereditary diseases, liver diseases, disorders of the central and peripheral nervous systems, and cardiovascular diseases. |
| Private | Equity | Initial Public Offering | | Lead Manager | Nasdaq:QURE | 91.8 | Healthcare |
| Equity | 2014-01-30 | 63.3 | | Cara Therapeutics Inc. | Shelton, CT
Cara Therapeutics Inc., a biotechnology company, engages in the development of therapeutics to treat pain and inflammation associated with diverse medical conditions. |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:CARA | 63.3 | Healthcare |
| Equity | 2014-01-30 | 103.5 | | Geron Corporation | Menlo Park, CA
Geron Corporation is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. |
| Public (Nasdaq:GERN) | Equity | URD / RD | | Co-Manager | Nasdaq:GERN | 103.5 | Healthcare |
| Equity | 2014-01-29 | 201.3 | | Fluidigm Corporation | South San Francisco, CA
Fluidigm Corporation develops, manufactures, and markets microfluidic systems for academic research institutions, clinical laboratories, pharmaceutical companies, and biotechnology and Ag-Bio companies. |
| Public (Nasdaq:FLDM) | Equity | Convertible | | Lead Manager | Nasdaq:FLDM | 201.3 | Healthcare |
| Equity | 2014-01-24 | 86.3 | | Derma Sciences, Inc. | Princeton, NJ
Derma Sciences, Inc. operates as a medical technology company primarily in the United States and Canada. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. |
| Public (Nasdaq:DSCI) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:DSCI | 86.3 | Healthcare |
| Equity | 2014-01-22 | 124.6 | | Nektar Therapeutics | San Francisco, CA
Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. |
| Public (Nasdaq:NKTR) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:NKTR | 124.6 | Healthcare |
| Equity | 2014-01-22 | 138.0 | | Acceleron Pharma, Inc. | Cambridge, MA
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. |
| Public (Nasdaq:XLRN) | Equity | Follow-On Offering | | Co-Lead Manager | Nasdaq:XLRN | 138.0 | Healthcare |
| Equity | 2014-01-08 | 101.1 | | GW Pharmaceuticals plc | Salisbury,
GW Pharmaceuticals plc researches, develops, and commercializes cannabinoid prescription pharmaceutical products for patients suffering from multiple sclerosis and cancer pain. |
| Public (Nasdaq:GWP) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:GWP | 101.1 | Healthcare |
| Equity | 2013-12-13 | 49.9 | | XOMA Corp | Berkeley, CA
Develops pharmaceutical products for infectious/immune system diseases |
| Public (Nasdaq:XOMA) | Equity | URD / RD | | Co-Manager | Nasdaq:XOMA | 49.9 | Healthcare |
| Equity | 2013-12-05 | 86.3 | | Endologix Inc | Irvine, CA
Develops treatments for vascular disease |
| Public (Nasdaq:ELGX) | Equity | Convertible | | Lead Manager | Nasdaq:ELGX | 86.3 | Healthcare |
| Equity | 2013-12-02 | 115.0 | | OREXIGEN Therapeutics Inc | La Jolla, CA
Neuroscience company developing strategic approches to the treatment of obesity |
| Public (Nasdaq:OREX) | Equity | Convertible | | Co-Manager | Nasdaq:OREX | 115.0 | Healthcare |
| Equity | 2013-11-21 | 74.0 | | Oxford Immunotec Global plc | Abingdon, UK
A commercial-stage diagnostics company providing tests in the field of immunology |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:OXFD | 74.0 | Healthcare |
| Equity | 2013-11-13 | 138.0 | | Tandem Diabetes Care Inc | Boston, MA
Manufacturer of the insulin pump |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:TNDM | 138.0 | Healthcare |
| Equity | 2013-10-31 | 57.5 | | Discovery Laboratories Inc | Warrington, PA
Researches and develops synthetic analogs of butyric acid intended to treat disorders characterized by abnormal cellular proliferation or disordered hemoglobin production |
| Public (Nasdaq:DSCO) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:DSCO | 57.5 | Healthcare |
| Equity | 2013-10-24 | 104.7 | | Novadaq Technologies Inc | Mississauga, ON
Develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and ophthalmic diseased and conditions |
| Public (Nasdaq:NVDQ) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:NVDQ | 104.7 | Healthcare |
| Equity | 2013-10-23 | 58.4 | | Mirati Therapeutics Inc | San Diego, CA
Biopharmaceutical company that develops treatments for cancer |
| Public (Nasdaq:MRTX) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:MRTX | 58.4 | Healthcare |
| Equity | 2013-10-08 | 64.0 | | Arrowhead Research Corp. | Pasadena, CA
Operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. |
| Public (Nasdaq:ARWR) | Equity | PIPE | $64 million PIPE | Joint Bookrunner | Nasdaq:ARWR | 64.0 | Healthcare |
| Equity | 2013-10-08 | 86.3 | | LDR Holding Corp | Austin, TX
Medical device company specializing in surgical and medical instruments |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:LDRH | 86.3 | Healthcare |
| Equity | 2013-09-26 | 874.1 | | Premier Inc | Charlotte, NC
Provides consulting services and information resources to help hospitals and health systems |
| Private | Equity | Initial Public Offering | | Co-Manager | Nasdaq:PINC | 874.1 | Healthcare |
| Equity | 2013-09-25 | 27.7 | | Idera Pharmaceuticals Inc | Sugar Land, TX
Engaged in development of genetic medicines based on antisense technology |
| Public (Nasdaq:IDRA) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:IDRA | 27.7 | Healthcare |
| Equity | 2013-09-24 | 100.0 | | Novavax Inc | Rockville, MD
Developer of drug delivery and vaccine technologies for women's healthcare and infectious diseases |
| Public (Nasdaq:NVAX) | Equity | Follow-On Offering | | Lead Manager | Nasdaq:NVAX | 100.0 | Healthcare |
| Equity | 2013-09-19 | 46.0 | | Sunshine Heart Inc | Redwood City, CA
Development of an implantable, mechanical heart assit device with an external driver specifically for the treatment of patients with a moderate to severe heart failure |
| Public (Nasdaq:SSH) | Equity | URD / RD | | Lead Bookrunner | Nasdaq:SSH | 46.0 | Healthcare |
| Equity | 2013-09-18 | 74.2 | | Sangamo BioSciences Inc | Cambridge, MA
Develops novel transcription factors for the regulation of gene expression |
| Public (Nasdaq:SGMO) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:SGMO | 74.2 | Healthcare |
| Equity | 2013-09-18 | 96.3 | | Acceleron Pharma Inc | Oakland, CA
Biopharmaceutical company involved in the development of novel protein therapeutics for cancer and rare diseases |
| Private | Equity | Initial Public Offering | | Lead Manager | Nasdaq:XLRN | 96.3 | Healthcare |
| Equity | 2013-09-17 | 150.4 | | Benefitfocus Inc | Charleston, SC
Software solutions provider for the healthcare industry |
| Private | Equity | Initial Public Offering | | Co-Manager | Nasdaq:BNFT | 150.4 | Healthcare |
| Equity | 2013-09-13 | 30.2 | | Nanosphere Inc | Northbrook, IL
Nanotechnology-based life sciences company |
| Public (Nasdaq:NSPH) | Equity | URD / RD | | Sole Bookrunner | Nasdaq:NSPH | 30.2 | Healthcare |
| Equity | 2013-09-10 | 112.4 | | Sagent Pharmaceuticals Inc | Schaumburg, IL
Specialty pharmaceutical company |
| Public (Nasdaq:SGNT) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:SGNT | 112.4 | Healthcare |
| Equity | 2013-08-08 | 39.0 | | Hansen Medical | Mountain View, CA
Developer of medical robotics designed for accurate positioning, manipulation, and stable control of catheters and catheter-based technologies. |
| Public (Nasdaq:HNSN) | Equity | PIPE | $39 million PIPE | Sole Bookrunner | Nasdaq:HNSN | 39.0 | Healthcare |
| Equity | 2013-08-07 | 52.1 | | Vanda Pharmaceuticals Inc | Scotts Valley, CA
Biopharmaceutical company focused on central nervous system disorders |
| Public (Nasdaq:VNDA) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:VNDA | 52.1 | Healthcare |
| Equity | 2013-07-24 | 66.0 | | Conatus Pharmaceuticals Inc | San Diego, CA
Specialty pharmaceutical company engaged in the development of human therapeutic drugs to treat liver disease |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:CNAT | 66.0 | Healthcare |
| Equity | 2013-07-24 | 89.1 | | Onconova Therapeutics Inc | Boulder, CO
Clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer |
| Private | Equity | Initial Public Offering | | Co-Manager | Nasdaq:ONTX | 89.1 | Healthcare |
| Equity | 2013-07-18 | 50.9 | | AcelRx Pharmaceuticals Inc | Redwood City, CA
Specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain |
| Public (Nasdaq:ACRX) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:ACRX | 50.9 | Healthcare |
| Equity | 2013-07-17 | 93.8 | | OncoMed Pharmaceuticals Inc | Redwood City, CA
Developers of novel therapeutics that target a new class of solid tumor cells |
| Private | Equity | Initial Public Offering | | Co-Manager | Nasdaq:OMED | 93.8 | Healthcare |
| Equity | 2013-06-14 | 28.1 | | Mast Therapeutics Inc | San Diego, CA
Pharmaceuticals manufacturer |
| Public (AMEX:MSTX) | Equity | Follow-On Offering | | Joint Bookrunner | AMEX:MSTX | 28.1 | Healthcare |
| Equity | 2013-06-04 | 132.3 | | Array Biopharma Inc | Plymouth, MN
Drug discovery company it creates small molecule drugs through the integration of chemistry, biology and informatics |
| Public (Nasdaq:ARRY) | Equity | Convertible | | Co-Manager | Nasdaq:ARRY | 132.3 | Healthcare |
| Equity | 2013-05-23 | 14.4 | | Venaxis Inc | Castle Rock, CO
Engaged in the discovery, research, development, manufacture, and licensing or marketing of novel drugs and diagnostics for human and animal healthcare |
| Public (Nasdaq:APPY) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:APPY | 14.4 | Healthcare |
| Equity | 2013-05-08 | 1089.5 | | Quintiles Transnational Holdings Inc | Durham, NC
Provider of biopharmaceutical development services and commercial outsourcing services |
| Private | Equity | Initial Public Offering | | Co-Manager | NYSE:Q | 1089.5 | Healthcare |
| Equity | 2013-05-01 | 16.5 | | Idera Pharmaceuticals Inc | Cambridge, MA
Engaged in development of genetic medicines based on antisense technology |
| Public (Nasdaq:IDRA) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:IDRA | 16.5 | Healthcare |
| Equity | 2013-04-25 | 98.3 | | Spectranetics Corp | Rockville, MD
Develop lasers to treat heart disease |
| Public (Nasdaq:SPNC) | Equity | Follow-On Offering | | Joint Bookrunner | Nasdaq:SPNC | 98.3 | Healthcare |
| Equity | 2013-04-25 | 90.0 | | Supernus Pharmaceuticals Inc | Colorado Springs, CO
Specialty pharmaceuticals company |
| Public (Nasdaq:SUPN) | Equity | Convertible | | Joint Bookrunner | Nasdaq:SUPN | 90.0 | Healthcare |
| Equity | 2013-04-11 | 64.0 | | Omthera Pharmaceuticals Inc | Boulder, CO
Specialty pharmaceutical company that develops drugs for heart disease |
| Private | Equity | Initial Public Offering | | Co-Manager | Nasdaq:OMTH | 64.0 | Healthcare |
| Equity | 2013-02-21 | 141.9 | | Achillion Pharmaceuticals Inc | New Haven, CT
Achillion was established for the discovery and commercial development of innovative therapeutic agents, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis and herpes viruses |
| Public (Nasdaq:ACHN) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:ACHN | 141.9 | Healthcare |
| Equity | 2013-02-20 | 32.0 | | Oncolytics Biotech Inc. | Calgary, Alberta,
Development stage biopharmaceutical company, focused on the discovery and development of pharmaceutical products for the treatment of cancers. |
| Public (Nasdaq:ONCY) | Equity | URD / RD | | Joint Bookrunner | Nasdaq:ONCY | 32.0 | Healthcare |
| Equity | 2013-01-31 | 2574.4 | | Zoetis Inc | Florham Park, NJ
Discoverer, developer, manufacturer, and marketer of a diverse portfolio of animal vaccines, medicines, biopharmaceuticals, diagnostics and genetic tests to prevent and treat disease in livestock and companion animals |
| Private | Equity | Initial Public Offering | | Co-Manager | NYSE:ZTS | 2574.4 | Healthcare |
| Equity | 2013-01-24 | 51.8 | | LipoScience Inc | Raleigh, NC
Developer of clinical diagnostic applications |
| Private | Equity | Initial Public Offering | | Joint Bookrunner | Nasdaq:LPDX | 51.8 | Healthcare |
| Equity | 2013-01-17 | 120.0 | | Pacira Pharmaceuticals Inc | South San Francisco, CA
Manufacturer of pharmaceutical products |
| Public (Nasdaq:PCRX) | Equity | Convertible | | Co-Manager | Nasdaq:PCRX | 120.0 | Healthcare |
| Equity | 2013-01-17 | 287.5 | | Theravance Inc | Parsippany, NJ
Biopharmaceutical company |
| Public (Nasdaq:THRX) | Equity | Convertible | | Co-Manager | Nasdaq:THRX | 287.5 | Healthcare |
| Equity | 2013-01-16 | 29.0 | | AtriCure Inc | West Chester, OH
Manufacturer and retailer of innovative surgical devices |
| Public (Nasdaq:ATRC) | Equity | URD / RD | | Sole Bookrunner | Nasdaq:ATRC | 29.0 | Healthcare |
| Equity | 2013-01-15 | 185.2 | | Alnylam Pharmaceuticals Inc | Cambridge, MA
Developer of RNAi therapeutics The RNAi is a natural cellular process for selectively turning off the activity of genes |
| Public (Nasdaq:ALNY) | Equity | Follow-On Offering | | Co-Manager | Nasdaq:ALNY | 185.2 | Healthcare |
| M&A | 2021-06-11 | 0 | | Briggs Healthcare, Inc. | Waukegan, IL
|
| | M&A | Carve Out | Piper Sandler served as sell-side advisor for Briggs Medical Service Company on divestiture of Stork to Aspen Surgical, a portfolio company of Audax Private Equity | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2021-06-09 | 435.0 | | Accolade, Inc | Plymouth Meeting, PA
|
| Public(Nasdaq:ACCD) | M&A | Buy-Side | Piper Sandler served as buy-side advisor for Accolade, Inc. on acquisition of PlushCare, Inc. | Financial Advisor | Nasdaq:ACCD | 435.0 | Healthcare |
| M&A | 2021-06-08 | 692.0 | | Interamerican Medical Center Group, LLC | Miami Lakes, FL
|
| Comvest Partners | M&A | Strategic Advisory | Piper Sandler served as financial advisor for IMC Medical Group Holdings LLC on its merger with CareMax Medical Group. The combined entity has been acquired by Deerfield Healthcare Technology Acquisitions Corp, a special purpose acquisition company | Financial Advisor | | 692.0 | Healthcare |
| M&A | 2021-05-31 | 0 | | Altaris Capital Partners, LLC | New York, NY
|
| | M&A | Buy-Side | Piper Sandler served as financial advisor for Altaris Capital Partners, LLC on acquisition of Solesis Medical Technologies, Inc. from Michelin | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2021-04-30 | 1100.0 | | The HydraFacial Company | Long Beach, CA
|
| Linden LLC; DW Healthcare Partners | M&A | Sell-Side | Piper Sandler served as sell-side advisor for The Hydrafaical Company, a portfolio company of Linden Capital Partners and DW Healthcare Partners, on sale to Vesper Healthcare Acquisition Corp. | Financial Advisor | Nasdaq:SKIN | 1100.0 | Healthcare |
| M&A | 2021-04-09 | 0 | | Ology Bioservices | Alachua, FL
|
| | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Ology Bioservices, Inc. to National Resilience, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2021-03-30 | 67.5 | | Aptevo Therapeutics Inc. | Seattle, WA
|
| | M&A | Strategic Advisory | Piper Sandler served as sell-side advisor for Aptevo Therapeutics Inc. on its sale of rights to receive royalty payments from Pfizer relating to RUXIENCE?, a commercial-stage biosimilar to Rituxan (Rituximab), to HealthCare Royalty Management, LLC | Financial Advisor | Nasdaq:APVO | 67.5 | Healthcare |
| M&A | 2021-03-01 | 0 | | Medical Mutual of Ohio | Cleveland, OH
|
| | M&A | Buy-Side | Piper Sandler served as buy-side advisor for Medical Mutual of Ohio on acquisition of ESI Employee Assistance Group | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2021-01-29 | 0 | | Surgical Specialties Corporation | Westwood, MA
|
| Vivo Capital, LLC | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Surgical Specialties Corp, backed by Vivo Capital and ZQ Capital, on sale to Corza Health, a portfolio company of GTCR | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-12-30 | 0 | BioDerm, Inc. | | M&A | Sell-Side | Piper Sandler served as sell-side advisor for BioDerm, Inc. on sale to Mountaingate Capital | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-12-29 | 340.0 | | Veran Medical Technologies | St. Louis, MO
|
| Private | M&A | Sell-Side | Piper Sandler served as exclusive financial advisor to Veran Medical Technologies on sale to Olympus Corporation. | Financial Advisor | | 340.0 | Healthcare |
| M&A | 2020-11-18 | 850.0 | | Key Surgical, Inc. | Minneapolis, MN
|
| Water Street Healthcare Partners | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Key Surgical, a portfolio company of Water Street Healthcare Partners, on sale to STERIS | Financial Advisor | | 850.0 | Healthcare |
| M&A | 2020-07-20 | 440.0 | | RTI Surgical Inc. | Deerfield, Illinois
|
| Public(Nasdaq:RTIX) | M&A | Carve Out | Piper Sandler served as sell-side advisor for RTI Surgical Holdings, Inc. on sale to Montagu Private Equity | Financial Advisor | Nasdaq:RTIX | 440.0 | Healthcare |
| M&A | 2020-05-27 | 76.0 | | Correvio Pharma Corp. | Vancouver, BC
|
| Public(Nasdaq:CORV) | M&A | Sell-Side | Piper SAndler served as sell-side advisor for Correvio Pharma Corp. on sale to ADVANZ PHARMA Corp. | Financial Advisor | Nasdaq:CORV | 76.0 | Healthcare |
| M&A | 2020-04-28 | 530.0 | | US WorldMeds, LLC | Louisville, KY
|
| Private | M&A | Carve Out | Piper Sandler served as sell-side advisor for US WorldMeds on sale of its CNS product portfolio to Supernus Pharmaceuticals | Financial Advisor | Private | 530.0 | Healthcare |
| M&A | 2020-04-16 | 0 | | Porton Biopharma Limited | Salisbury, WT
|
| Private | M&A | Strategic Advisory | Piper Sandler served as exclusive financial advisor for Porton Biopharma Limited on exclusive licence agreement for worldwide marketing, sales and distribution of Erwinaze/Erwinase, a commercial biopharmaceutical product, to Clinigen Group plc | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-04-01 | 0 | | JM Smith Corporation | Spartanburg, SC
|
| Private | M&A | Sell-Side | Piper Sandler served as sell-side advisor for J M Smith Corporation on sale of its technology and services division, Smithtech Ltd., now called redSail Technologies, to Francisco Partners Management, L.P | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-04-01 | 110.0 | | Heska Corporation | Loveland, CO
|
| Public(Nasdaq:HSKN) | M&A | Buy-Side | Piper Sandler served as buy-side advisor for Heska Corporation on acquisition of scil animal care company GmbH from Covetrus, Inc. | Financial Advisor | Nasdaq:HSKN | 110.0 | Healthcare |
| M&A | 2020-03-10 | 0 | | Merck & Co. Inc. | Kenilworth, NJ
|
| Public(NYSE:MRK) | M&A | Sell-Side | Piper Sandler served as sell-side advisor for The StayWell Company, LLC, a subsidiary of Merck & Co., Inc. and portfolio company of Vestar Capital Partners, on sale to WebMD Health Corp. | Financial Advisor | NYSE:MRK | Undisclosed | Healthcare |
| M&A | 2020-03-02 | 0 | | ParcelShield, LLC | Redmond, OR
|
| Private | M&A | Sell-Side | Piper Sandler served as sell-side advisor for ParcelShield Holdings, LLC on sale to Excellere Capital Management, LLC | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-02-28 | 100.0 | | Aptevo Therapeutics Inc. | Seattle, WA
|
| Public(Nasdaq:APVO) | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Aptevo Therapeutics Inc. on sale of its commercial-stage Hemophilia B product, to Medexus Pharmaceuticals, Inc. | Financial Advisor | Nasdaq:APVO | 100.0 | Healthcare |
| M&A | 2020-02-21 | 0 | | Intelerad Medical Systems Incorporated | Montreal, QC
|
| Private | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Intelerad Medical Systems, Inc., a portfolio company of Novacap, on sale of a majority stake to Hg Capital | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-02-20 | 260.0 | | IWG High Performance Conductors, Inc. | Inman, SC
|
| Private | M&A | Sell-Side | Piper Sandler served as sell-side advisor for IWG High Performance Conductors, a segment of International Wire Group Holdings, Inc., a portfolio company of Atlas Holdings LLC on sale to Teleflex | Financial Advisor | | 260.0 | Healthcare |
| M&A | 2020-02-13 | 0 | | Concerned Dental Care | , NY
|
| | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Concerned Dental Care on sale to Affinity Dental Management, a portfolio company of MidOcean Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-02-12 | 525.0 | | Laborie Medical Technologies, Inc. | Mississauga, ON
|
| Patricia Industries AB | M&A | Buy-Side | Piper Sandler served as buy-side advisor for Laborie Medical Technologies, a portfolio company of Patricia Industries, on acquisition of Clinical Innovations, LLC, a portfolio company of EQT | Financial Advisor | | 525.0 | Healthcare |
| M&A | 2020-01-28 | 0 | | NeuroInternational LLC | Sarasota, FL
|
| Imperial Capital Group Ltd. | M&A | Sell-Side | Piper Sandler served as sell-side advisor for NeuroInternational Healthcare, LLC, a portfolio company of Imperial Capital, on sale to National Mentor Holdings, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2020-01-21 | 111.0 | | Blueprint Genetics Oy | Helsinki, FI
|
| Private | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Blueprint Genetics Oy on sale to Quest Diagnostics | Financial Advisor | | 111.0 | Healthcare |
| M&A | 2020-01-02 | 0 | | McKesson Corporation | San Francisco, CA
|
| Public (NYSE:MCK) | M&A | Carve Out | Piper Sandler served as sell-side advisor for McKesson Corporation on divestiture of its Patient Care Solutions business to AdaptHealth Corp. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-12-30 | 0 | | Evariant, inc. | Farmington, CT
|
| Health Enterprise Partners | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Evariant, Inc., a portfolio company of Goldman Sachs and Health Enterprise Partners, on sale to Heathgrades, Inc., a portfoilo company of Vestar Capital Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-12-19 | 8.4 | | Mauna Kea Technologies SAS | Paris, FR
|
| Public (EPA:MKEA) | M&A | Strategic Advisory | Piper Sandler served as exclusive financial advisor for Mauna Kea Technologies SA on strategic equity investment from Johnson & Johnson Innovation | Financial Advisor | | 8.4 | Healthcare |
| M&A | 2019-11-21 | 0 | | Providien, LLC | Scottsdale, AZ
|
| Endeavour Capital | M&A | Sell-Side | Piper Sandler served as sell-side advisor for Providien, LLC, a portfolio company of Endeavour Capital, on sale to Carlisle Companies Incorporated | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-11-14 | 865.4 | | National Seating & Mobility, Inc. | Franklin, TN
|
| Court Square Capital Partners L.P. | M&A | Sell-Side | Piper Sandler served as co-advisor for National Seating & Mobility, Inc. on investment from Cinven | Financial Advisor | Private | 865.4 | Healthcare |
| M&A | 2019-10-31 | 0 | | Censis Technologies | Franklin, TN
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Censis Technologies, Inc., a portfolio company of The Riverside Company, on sale to Fortive Corporation | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-10-01 | 52.0 | TSO3 Inc. | Private | M&A | Sell-Side | Piper Sandler served as sell-side advisor for TSO3 Inc. on sale to Stryker Corporation | Financial Advisor | | 52.0 | Healthcare |
| M&A | 2019-10-01 | 0 | | Merck & Co. Inc. | Kenilworth, NJ
|
| Public (NYSE:MRK) | M&A | Carve Out | Piper Sandler served as sell-side advisor for Merck & Co. Inc. on divestiture of Aptus Health, Inc. to WebMD Health Corporation | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-08-30 | 0 | | ICU Medical, Inc. | San Clemente, CA
|
| Public (Nasdaq:ICUI) | M&A | Buy-Side | Piper Sandler served as buy-side advisor for ICU Medical, Inc. on acquisition of Pursuit Vascular, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-08-27 | 275.0 | | Cardiac Science Corporation | Deerfield, WI
|
| Public (Nasdaq:CSCX) | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Cardiac Science Corporation, a portfolio company of Aurora Resurgence, on sale to ZOLL Medical Corporation | Financial Advisor | | 275.0 | Healthcare |
| M&A | 2019-08-13 | 180.0 | | AtriCure, Inc. | West Chester, OH
|
| Public (Nasdaq:ATRC) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for AtriCure, Inc. on acquisition of SentreHEART Inc. | Financial Advisor | | 180.0 | Healthcare |
| M&A | 2019-08-01 | 0 | | Collagen Matrix, Inc. | Oakland, NJ
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Collagen Matrix, a portfolio company of Metalmark Capital, on sale to Linden Capital Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-07-01 | 0 | | US WorldMeds, LLC | Louisville, KY
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for U.S. WorldMeds, LLC on divestiture of Sloan Pharma, S.a.r.l, a wholly-owned subsidiary, to ZELNORM (tegaserod) and all its global rights to Alfasigma USA, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-03-26 | 0 | | Envy Medical, Inc. | Westlake Village, CA
|
| HCP & Company | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Envy Medical, Inc., a portfolio company of HCP & Company, on sale to Allergan, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-03-18 | 0 | | Edge Therapeutics, Inc. | Berkeley Heights, NJ
|
| Public (Nasdaq:PDSB) | M&A | Sell-Side | Piper Jaffray served as exclusive financial advisor for Edge Therapeutics, Inc. on reverse merger with PDS Biotechnology Corporation | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-03-13 | 0 | | OMNI life science, Inc. | East Taunton, MA
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for OMNI Orthopaedics, Inc. on sale to Corin Group plc, a portfolio company of Permira Funds | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-03-08 | 300.0 | | RTI Surgical Inc. | Alachua, FL
|
| Public (Nasdaq:RTIX) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for RTI Surgical, Inc. on acquisition of Paradigm Spine, LLC | Financial Advisor | | 300.0 | Healthcare |
| M&A | 2019-03-05 | 150.0 | | Tabula Rasa Healthcare, Inc. | Moorestown, NJ
|
| Public (Nasdaq:TRHC) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for Tabula Rasa HealthCare, Inc. on acquisition of Prescribe Wellness, LLC | Financial Advisor | | 150.0 | Healthcare |
| M&A | 2019-03-05 | 0 | | Orchid Orthopedic Solutions, LLC | Holt, MI
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Orchid Orthopedic Solutions LLC, a portfolio company of Altor Equity Partners, on sale to Nordic Capital Limited | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2019-02-21 | 2000.0 | | Nxstage Medical, Inc. | Lawrence, MA
|
| Public (Nasdaq:NXTM) | M&A | Sell-Side | Piper selected as sell-side advisor for NxStage Medical, Inc. on sale to Fresenius Medical Care | Financial Advisor | | 2000.0 | Healthcare |
| M&A | 2019-01-22 | 0 | | Medical Instrument Development Laboratories, Inc. | San Leandro, CA
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Medical Instrument Development Laboratories, Inc. on sale to Hoya Surgical Optics | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-11-27 | 0 | Viverae Inc. | Frontier Capital | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for SimplyWell, Inc., a portfolio company of Frontier Capital, on sale to Virgin Pulse, Inc., a portfolio company of Marlin Equity Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-11-13 | 200.0 | | Merit Medical Systems, Inc. | South Jordan, UT
|
| Public (Nasdaq:MMSI) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for Merit Medical Systems, Inc. on purchase of Cianna Medical, Inc. | Financial Advisor | | 200.0 | Healthcare |
| M&A | 2018-11-09 | 1401.0 | | K2M Group Holdings, Inc. | VA, Stryker Corporation
Leesburg |
| Public (Nasdaq:KTWO) | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for K2M Group Holdings, Inc. on sale to Stryker Corporation | Financial Advisor | | 1401.0 | Healthcare |
| M&A | 2018-11-05 | 135.0 | | Huadong Medicine Co., Ltd | ,
|
| Public (SHE:000963) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for Huadong Medicine Co., Limited on acquisition of Sinclair Pharma plc | Financial Advisor | | 135.0 | Healthcare |
| M&A | 2018-09-24 | 0 | | Bellus Medical, LLC | Addison, TX
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Bellus Medical, LLC on sale to Crown Laboratories, Inc, a portfolio company of Hildred Capital Partners, LLC | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-08-30 | 97.0 | | Bovie Medical Corporation | Clearwater, Florida
|
| Public (Nasdaq:BVX) | M&A | Carve Out | Piper Jaffray served as sole financial advisor for Bovie Medical Corporation on divestiture of its Core Business Segment to Symmetry Surgical | Financial Advisor | | 97.0 | Healthcare |
| M&A | 2018-08-21 | 77.0 | | Shanghai Kinetic Medical Co., Ltd. | Shanghai,
|
| Public (SHE:300326) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for Shanghai Kinetic Medical on purchase of elliquence, LLC | Financial Advisor | | 77.0 | Healthcare |
| M&A | 2018-07-31 | 1994.3 | | Abaxis, Inc. | Union City, CA
|
| Public (Nasdaq:ABAX) | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Abaxis, Inc. on sale to Zoetis Inc. | Financial Advisor | | 1994.3 | Healthcare |
| M&A | 2018-07-24 | 0 | | Bioventus LLC | Durham, North Carolina
|
| Private | M&A | Sell-Side | Piper Jaffray served as exclusive M&A advisor to Bioventus on sale of its next generation bone morphogenetic protein (?BMP?) development program to Viscogliosi Brothers, LLC | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-07-06 | 0 | | TVA Medical, Inc. | Austin, TX
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for TVA Medical, Inc. on sale to Becton Dickinson and Company | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-07-02 | 600.0 | | Integer Holdings Corporation | Frisco, TX
|
| Public (NYSE:ITGR) | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Integer Holdings Corporation on sale of its Advanced Surgical and Orthopedics ("AS&O") product lines to MedPlast, LLC | Financial Advisor | | 600.0 | Healthcare |
| M&A | 2018-07-02 | 0 | | Create Group NYC, LLC | New York, NY
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Create Group NYC, LLC on sale to UDG Healthcare plc | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-06-29 | 375.0 | | Counsyl, Inc. | San Francisco, CA
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Counsyl, Inc. on sale to Myraid Genetics | Financial Advisor | | 375.0 | Healthcare |
| M&A | 2018-05-21 | 0 | | Cadence, Inc. | Staunton, VA
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Cadence, Inc. on sale to Kohlberg & Company | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-04-27 | 0 | | NXThera, Inc. | Maple Grove, MN
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for NxThera Inc. on sale to Boston Scientific | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-04-04 | 0 | | Astute Medical, Inc. | San Diego, CA
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Astute Medical, Inc. on sale to bioMérieux S.A. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-03-13 | 0 | | RxAdvance Corporation | Southborough, MA
|
| Private | M&A | Sell-Side | Piper Jaffray served as exclusive financial advisor for RxAdvance on significant investment received from Centene Corporation | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-02-28 | 0 | | Entellus Medical, Inc. | Plymouth, MN
|
| Public (Nasdaq:ENTL) | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Entellus Medical, Inc. on sale to Stryker Corporation | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-02-16 | 0 | | HealthFair, Inc. | Winter Park, FL
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for HealthFair, Inc. on sale to Community Care Health Network d.b.a. Matrix Medical Network | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-02-15 | 0 | | Merit Medical Systems, Inc. | South Jordan, UT
|
| Public (Nasdaq:MMSI) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for Merit Medical Systems, Inc. on acquisition of Becton, Dickson and Co. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2018-01-30 | 0 | | Innovate Biopharmaceuticals, Inc. | Raleigh, NC
|
| Private | M&A | Strategic Advisory | Piper Jaffray served as exclusive financial advisor for Innovate Biopharmaceuticals, Inc. on merger with Monster Digital, Inc. d.b.a. SDJ Technologies, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-12-21 | 0 | | Aura Biosciences, Inc. | Cambridge, MA
|
| Private | M&A | Sell-Side | Piper Jaffray served as exclusive financial advisor and placement agent for Aura Biosciences, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-12-18 | 0 | | EltaMD | Carrollton, TX
Manufactures and supplies medical grade skincare products |
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for EltaMD Holdings Inc. on sale to Colgate-Palmolive Company
| Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-12-05 | 0 | MDVIP Inc. | Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for MDVIP, a portfolio company of Summit Partners, on sale to Leonard Green | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-28 | 0 | | Calimmune, Inc. | Tuscon, AZ
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Calimmune, Inc. on sale to CSL Ltd. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-15 | 0 | | Covenant Surgical Partners, Inc. | Nashville, TN
Covenant is a leading acquirer and operator of ambulatory surgery centers and physician practices. The company currently provides gastrointestinal and ophthalmic procedures through 37 ASC and physician practice locations across 17 states. |
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Covenant Surgical Partners, Inc.on sale to KKR & Co. L.P. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-14 | 0 | | MicroMass Communications Inc. | Cary, NC
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for MicroMass Communications Inc., a portfolio company of Periscope Equity, on sale to UDG Healthcare plc | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-13 | 0 | | Humanwell Healthcare (Group) Co.,Ltd. | Wuhan, CN
Humanwell is a public company headquartered in Wuhan, China and listed on the Shanghai Stock Exchange. It operates as a fully integrated healthcare solution provider in over 10 countries. Humanwell is one of the largest providers of anesthetics and fertil |
| Public (SHES:600079) | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for Humanwell Healthcare (Group) Co.,Ltd on acquisition of The Ritedose Corporation
| Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-12 | 0 | | G&H Orthodontics | Franklin, IN
G&H is a premier designer, manufacturer, and distributor of clinical orthodontic products. The company offers the broadest line of in-house manufactured orthodontic wires, brackets, bands & tubes and elastomerics in the industry and also supplies related |
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for G&H Orthodontics on sale to Altaris Capital Partners, LLC | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-12 | 0 | | Merritt Veterinary Supplies, Inc. | Columbia, SC
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Merritt Veterinary Supplies on sale to Henry Schein, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-06 | 0 | | TearScience, Inc. | Morrisville, NC
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for TearScience, Inc. on sale to Johnson & Johnson Vision | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-09-01 | 0 | | Altimmune, Inc. | Gaithersburg, MD
Altimmune is a biopharmaceutical company focused on influenza, hepatitis B, anthrax and oncology. |
| Private | M&A | Sell-Side | Piper Jaffray served as financial advisor for Altimmune, Inc. on merger with PharmAthene, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-08-31 | 0 | | Aptevo Therapeutics Inc. | Seattle, WA
|
| Public (Nasdaq:AVPO) | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Aptevo Therapeutics Inc. on sale of its commercial portfolio of hyperimmune products to Saol Therapeutics Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-08-08 | 0 | | Cirtec Medical Systems, LLC | Los Gatos, CA
|
| Private | M&A | Sell-Side | Piper Jaffray served as sell-side advisor for Cirtec Medical Systems, LLC, a portfolio company of Century Park Capital Partners, on sale to 3i Group plc | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-07-18 | 0 | Teladoc, Inc. | Private | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for Teladoc, Inc. on acquisition of Best Doctors Inc, a portfolio company of BBH Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-06-19 | 0 | | JustRight Surgical, LLC | Louisville, CO
|
| Private | M&A | Buy-Side | Piper Jaffray served as buy-side advisor for JustRight Surgical, LLC on license agreement with Intuitive Surgical, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-05-10 | 0 | | Otic Pharma Ltd. | Or Yehuda, ISR
A pharmaceutical company that manufactures foam based solutions for the delivery of medications to treat ear disorders. |
| Private | M&A | Sell-Side | Merger with Tokai Pharmaceuticals | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-05-10 | 0 | | Cochlear Ltd. | Sydney, AUS
Provides implantable hearing solutions. |
| Public (ASX:COH) | M&A | Buy-Side | Acquired Sycle, LLC | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-04-21 | 0 | | Fotona d.d. | Ljubljana, Slovenia,
Engages in the design, manufacture, and support of advanced solid-state laser systems for medicine, dentistry, and industry and defense applications. |
| Private | M&A | Sell-Side | Sold to AGIC Capital | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-03-10 | 0 | | Surgical Specialties Corporation | Reading, PA
Manufactures surgical products. The company offers suture needles, sutures, microsurgical cutting instruments, eye garters, and ophthalmic cannulas. |
| Private | M&A | Sell-Side | Sold to Vivo Capital, LLC | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-03-09 | 0 | | PromptCare Inc. | Clark, NJ
Pprovides home-based specialty respiratory and infusion therapy services. |
| Private | M&A | Sell-Side | Sold to The Halifax Group. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2017-01-17 | 0 | | Encore Vision, Inc. | Fort Worth, TX
Encore Vision, Inc. specializes in high quality, cost effective eyewear products and accessories. |
| Private | M&A | Sell-Side | Sold to Novartis AG | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-12-30 | 0 | | Apollo Endosurgery, Inc. | Austin, TX
A medical device company, focused on the development and distribution of less invasive products for the treatment of obesity and other gastrointestinal disorders. |
| Private | M&A | Sell-Side | Reverse merger with Lpath Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-08-08 | 0 | | Medtronic plc | Dublin, Ireland,
Healthcare solutions company providing medical technologies, services, and solutions worldwide. |
| Public (NYSE:MDT) | M&A | Buy-Side | Acquired the gynecology business from Smith & Nephew plc | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-07-06 | 0 | | DFINE Inc. | San Jose, CA
A medical device company, develops minimally invasive radiofrequency targeted therapeutic devices that are used to treat pathologies of the vertebrae. |
| Private | M&A | Sell-Side | Sold to Merit Medical Systems (Nasdaq:MMSI) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-07-01 | 0 | | Audigy Group | Vancouver, WA
Provides business management services for hearing care practices to private practice audiologists and hearing care professionals in the United States. |
| Private | M&A | Sell-Side | Sold to GN ReSound | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-06-21 | 0 | | Specialty Silicone Fabricators, Inc. | Paso Robles, CA
Develops and manufactures silicone, silicone-based products, and thermoplastics for the medical device and pharmaceutical markets. |
| Private | M&A | Sell-Side | Sold to Trelleborg AB | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-05-16 | 0 | | Cayenne Medical, Inc. | Scottsdale, AZ
Medical device company, designs, develops, and markets soft tissue reconstruction solutions for the knee, shoulder, and extremities. |
| Private | M&A | Sell-Side | Sold to Zimmer Biomet Holdings (NYSE: ZBH) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-04-01 | 0 | | Douglas Scientific | Alexandria, MN
A rapidly growing laboratory automation company. |
| Private | M&A | Sell-Side | Sold to LGC, a portfolio company of KKR | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-02-11 | 0 | | Ellipse Technologies, Inc. | Aliso Viejo, CA
Designs and develops non-invasively adjustable, remote controlled implants for spinal and orthopedic applications. |
| Private | M&A | Sell-Side | Sold to NuVasive (Nasdaq:NUVA) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-02-11 | 0 | | Vizient, Inc. | Irving, TX
Operates a network of not-for-profit health care organizations to improve performance and efficiency in clinical, financial, and operational management. |
| Private | M&A | Buy-Side | Acquired Spend and Clinical Resource Management division of MedAssets from Pamplona Capital. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-02-02 | 0 | | Creganna Medical | Galway, Ireland,
Provider of outsourced design and manufacturing services to the medical device industry |
| Private | M&A | Sell-Side | Announced sale to TE Connectivity (NYSE:TEL) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-01-20 | 0 | | On-X Life Technologies Inc. | Austin, TX
Develops, manufactures, and markets artificial heart valve replacement and repair products. |
| Private | M&A | Sell-Side | Sold to CryoLife Inc. (NYSE:CRY) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-01-08 | 0 | | Healthland Inc. | Minneapolis, MN
Designs and develops healthcare information technology solutions for rural community and critical access hospitals, clinics and health centers. |
| Private | M&A | Sell-Side | Sold to Computer Programs and Systems Inc. (Nasdaq:CPSI) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-01-05 | 0 | | Blue Belt Technologies Inc. | Plymouth, MN
Developer of small surgical instruments for use in orthopedic procedures. |
| Private | M&A | Sell-Side | Sold to Smith & Nephew plc (NYSE:SN) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-01-04 | 0 | | Surgiquest, Inc. | Milford, CT
Develops, manufactures, and markets technology solutions for minimally invasive surgery. |
| Private | M&A | Sell-Side | Sold to CONMED Corporation | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2016-01-04 | 0 | | Center for Vein Restoration | Greenbelt, MA
Provides clinical procedures for the treatment of varicose veins and spider veins caused by venous insufficiency. |
| Private | M&A | Sell-Side | Sold to Cortec Group | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-11-25 | 0 | | PDR Network LLC | Montvale, NJ
Develops a drug information and safety network for pharmaceutical manufacturers, the United States physicians, physician groups, physician assistants, and other health care professionals. |
| Private | M&A | Sell-Side | Sold to Genstar Capital | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-11-09 | 0 | | International Pharmaceutical Generics | Ottowa, ON
Generic pharmaceutical manufacturer. |
| Private | M&A | Sell-Side | Sold to Emcure Pharmaceuticals, a portfolio company of Bain Capital Partners. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-10-31 | 0 | | AtriCure, Inc. | West Chester, OH
Provides atrial fibrillation solutions worldwide. |
| Private | M&A | Buy-Side | Acquired nContact, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-10-30 | 0 | | Community Veterinary Partners LLC | Bala Cynwyd, PA
Provides solutions for veterinary professionals. |
| Private | M&A | Sell-Side | Sold to Cortec Group | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-10-26 | 0 | | Endologix, Inc. | Irvine, CA
Ddevelops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms. |
| Public (Nasdaq:ELGX) | M&A | Buy-Side | Announced merger with TriVascular Technologies, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-10-19 | 0 | | Cyberonics, Inc. | Houston, TX
Designs, develops, markets, and sells implantable medical devices to hospitals and ambulatory surgery centers. |
| Public (Nasdaq:CYBX) | M&A | Sell-Side | Merged with with Sorin Group. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-10-02 | 0 | | Medtronic plc | Dublin, Ireland,
Healthcare solutions company providing medical technologies, services, and solutions worldwide. |
| Public (NYSE:MDT) | M&A | Fairness Opinion | Provided fairness opinion to Medtronic on acquisition of Twelve, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-10-01 | 0 | | Greatbatch, Inc. | Frisco, TX
Provider of technology solutions for medical and industrial applications. |
| Public (NYSE:GB) | M&A | Buy-Side | Announced acquisition of Lake Region Medical. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-09-29 | 0 | | Caring Brands International | Sunrise, FL
Provides home care, hospice, and medical staffing services in the United States. |
| Private | M&A | Sell-Side | Sold to Levine Leichtman Capital Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-08-31 | 0 | | Medical Solutions LLC | Omaha, NE
Operates as a healthcare staffing company in the United States. |
| Private | M&A | Sell-Side | Sold to Beecken Petty O'Keefe & Company. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-07-17 | 0 | | TEI Biosciences Inc. | Waltham, MA
Develops and commercializes biological products for soft tissue repair and reinforcement applications. |
| Private | M&A | Sell-Side | Sold to Integra LifeSciences Holdings Corporation (Nasdaq:IART) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-07-13 | 0 | | RF Surgical Systems, Inc. | Bellevue, WA
Offers radio frequency (RF) assure detection system that is used for detecting and preventing retained surgical sponges. |
| Private | M&A | Sell-Side | Announced sale to Medtronic (NYSE:MDT). | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-07-02 | 0 | | Integra LifeSciences Holdings Corporation | Plainsboro, NJ
Develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. |
| Public (Nasdaq:IART) | M&A | Carve Out | Spin-off of SeaSpine into publicly traded company. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-06-30 | 0 | | Stratose, Inc. | Atlanta, GA
Provides healthcare cost containment services in the United States. |
| Private | M&A | Sell-Side | Sold to Parthenon Capital Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-06-18 | 0 | | CardioInsight Technologies Inc. | Cleveland, OH
Develops a cardiac mapping technology to map electrical disorders of the heart. |
| Private | M&A | Sell-Side | Sold to Medtronic plc (NYSE:MDT) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-06-17 | 0 | | OptumInsight, Inc. | Eden Prairie, MN
Provides analytics, technology, and consulting services to improve the performance of health systems. |
| Private | M&A | Carve Out | Sold Picis division of OptumInsight to Constellation Software (TSX:CSU) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-04-13 | 0 | | AdvancedCath Technologies Inc. | San Jose, CA
Develops and manufactures balloons, catheters, coils, ground cores, and finished guidewires. |
| Private | M&A | Sell-Side | Sold to TE Connectivity | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-04-01 | 0 | | VHA Inc. | Irving, TX
Provides health care industry-related services to members who join the company's cooperative network. |
| Private | M&A | Sell-Side | Merged with University HealthSystem Consortium Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-03-31 | 70.9 | | Cogentix Medial, Inc. | Minnetonka, MN
Engages in the development, manufacture, and marketing of products for the treatment of voiding dysfunctions. |
| Public (Nasdaq:CGNT) | M&A | Sell-Side | Merged with Vision-Sciences, Inc. | Financial Advisor | (Nasdaq:CGNT) | 70.9 | Healthcare |
| M&A | 2015-03-04 | 0 | | AdvancedCath Technologies Inc. | San Jose, CA
Develops and manufactures balloons, catheters, coils, ground cores, and finished guidewires. |
| Private | M&A | Sell-Side | Sold to TE Connectivity Ltd. (NYSE:TEL) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-02-27 | 0 | | MediMedia USA, Inc. | Yardley, PA
Provides formulary information services. |
| Private | M&A | Carve Out | Sold MediMedia's Pharma Solutions business to ICON PLC | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2015-01-15 | 35.0 | | Advanced Circulatory Systems Inc | Saint Paul, MN
Manufactures and markets advanced circulatory technology. |
| Private | M&A | Sell-Side | Sold to Zoll Medical Corporation | Financial Advisor | | 35.0 | Healthcare |
| M&A | 2014-12-31 | 0 | | Precision Wire Components, LLC | Tualatin, OR
Offers custom medical wire components and services for medical device original equipment manufacturers in the United States. |
| Private | M&A | Sell-Side | Sold to Creganna-Tactx Medical | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-12-31 | 0 | | Uroplasty, Inc. | Minnetonka, MN
Engages in the development, manufacture, and marketing of products for the treatment of voiding dysfunctions. |
| Public (Nasdaq:URI) | M&A | Sell-Side | Sold to Vision-Sciences Inc. | Financial Advisor | Nasdaq:UPI | Undisclosed | Healthcare |
| M&A | 2014-12-31 | 0 | | UnitedHealth Group Incorporated (OptumInsight's CareTracker) | Minnetonka, MN
A leading provider of fully integrated, cloud-based electronic medical record and practic management solutions for physician practices. |
| Public (NYSE:UNH) | M&A | Carve Out | Sold CareTracker, a division of UnitedHealth Group, to Constellation Software, Inc. | Financial Advisor | NYSE:UNH | Undisclosed | Healthcare |
| M&A | 2014-11-18 | 0 | | TGaS Advisors, LLC | East Norriton, PA
Provides benchmarking and advisory services to pharmaceutical and biopharmaceutical commercial operations companies. |
| Private | M&A | Sell-Side | Sold to a group consisting of Senior Management and Gemini Investors | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-11-03 | 0 | | LDM Group, LLC | St. Louis, MO
Provides behavior based prescription management programs. |
| Private | M&A | Sell-Side | Sold to PDR Network, a portfolio company of Lee Equity Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-11-03 | 0 | | RedPath Integrated Pathology, Inc. | Pittsburgh, PA
Provides molecular diagnostic and clinical testing services for gastroenterologists, pathologists, and other clinicians to diagnose cancer. |
| Private | M&A | Sell-Side | Sold to Interpace Diagnostics, a subsidiary of PDI, Inc. (Nasdaq:PDII) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-11-03 | 0 | | The Spectranetics Corporation | Colorado Springs, CO
Develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. |
| Public (Nasdaq:SPNC) | M&A | Buy-Side | Acquired Covidien's Stellarex Drug Coated Balloon Assets | Financial Advisor | Nasdaq:SPNC | Undisclosed | Healthcare |
| M&A | 2014-10-30 | 0 | | FH Orthopedics | Heimsbrunn, France,
A leading French orthopedics player with a broad product portfolio including Joint Replacement, Extremities and Sports Medicine. |
| Private | M&A | Sell-Side | Sold to LBO France | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-09-09 | 0 | | eCardio Diagnostics, LLC | Houston, TX
Provides remote cardiac monitoring products and services for arrhythmia diagnosis. |
| Private | M&A | Sell-Side | eCardio Diagnostics and Preventice Inc. completed a merger-of-equals, to be owned by Merck GHIF | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-09-02 | 0 | | Roche Innovation Center Copenhagen A/S | Horsholm, Denmark,
A biopharmaceutical compan, focused on the discovery and development of RNA-targeted therapies internationally. |
| Private | M&A | Sell-Side | Sold to Roche Holding AG (SWX:ROG) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-08-31 | 0 | | Santaris Pharma A/S | Horsholm, Copenhagen,
A biopharmaceutical company focused on the discovery and development of RNA-targeted therapies internationally |
| Private | M&A | Sell-Side | Sold to Roche Holdings (SWX:ROG) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-08-11 | 0 | | Avalon Laboratories, LLC | Rancho Dominguez, CA
Manufactures and supplies cardiovascular and cardiopulmonary catheters and cannulae to healthcare suppliers, biomedical companies, and distributors. |
| Private | M&A | Sell-Side | Sold to Nordson Corporation (Nasdaq:NDSN) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-08-07 | 0 | | NeuroTherm Inc. | Wilmington, MA
Developer and manufacturer of minimally invasive solutions for pain management |
| Private | M&A | Sell-Side | Sold to St. Jude Medical | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-07-18 | 0 | | HemaSource, Inc. | West Jordan, UT
Distributes medical disposable products used in blood therapies markets. |
| Private | M&A | Sell-Side | Sold to Graham Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-07-01 | 0 | | Smartpak Equine, LLC | Plymouth, MA
Online retailer of animal products in the United States. |
| Private | M&A | Sell-Side | Sold to Henry Schein (Nasdaq:HSIC) and Oak Hill Capital Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-06-30 | 0 | | Small Bone Innovations, Inc. | New York, NY
Manufactures and supplies orthopedics devices and instruments to treat trauma and diseases in small bones and joints |
| Private | M&A | Sell-Side | Sold to Stryker Corp. (NYSE:SYK) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-06-30 | 0 | | The Spectranetics Corporation | Colorado Springs, CO
Develops single-use medical devices used in minimally invasive procedures in the cardiovascular system. |
| Public (Nasdaq:SPNC) | M&A | Buy-Side | Acquired AngioScore, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-06-30 | 0 | | Xitogen Technologies, Inc. | Suzhou, CH
A pre-revenue company that has developed a next generation flow cytometer in China. |
| Private | M&A | Sell-Side | Announced sale to Beckman Coulter Life Sciences | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-06-17 | 0 | | AtheroMed, Inc. | Menlo Park, CA
Develops treatments for peripheral arterial disease. |
| Private | M&A | Sell-Side | Sale to Volcano Corporation (Nasdaq:VOLC) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-06-10 | 0 | | MDVIP Inc. | Boca Raton, FL
Provides personalized and preventive healthcare services that assist physicians and institutions. |
| Private | M&A | Carve Out | Sold to Summit Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-05-29 | 0 | | Arthrocare Corporation | Austin, TX
Multi-business medical device company that develops, manufactures and markets minimally invasive surgical products. |
| Private | M&A | Take Private | Sale to Smith & Nephew plc | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-05-09 | 0 | | RecoverCare, LLC | Louisville, KY
Leading distributor of therapeutic support surfaces, bariatric, wound care, and safe patient handling equipment. |
| Private | M&A | Sell-Side | RecoverCare and Joerns Healthcare, a portfolio company of Quad-C Management, completed a merger-of-equals | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-05-08 | 0 | | California Stem Cell, Inc. | Irvine, CA
Engages in the discovery, production, and supply of human cell populations for research, diagnostic, clinical, and therapeutic applications. |
| Private | M&A | Sell-Side | Sale to Neostem, Inc. (Nasdaq: NBS) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-04-02 | 0 | | Cardinal Health, Inc. | Dublin, OH
Healthcare services company focused on improving the cost-effectiveness of healthcare. |
| Public (NYSE:CAH) | M&A | Buy-Side | Acquired AccessClosure, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-03-12 | 0 | | Lake Region Medical, Inc. | Chaska, MN
Original development manufacturer to the cardiology and vascular medical device industry. |
| Private | M&A | Sell-Side | Sold to Accellent Inc., a portfolio company of Kohlberg Kravis Roberts and Bain Capital | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-02-28 | 0 | | Fluidigm Corporation | South San Francisco, CA
Develops and manufactures microfluidic systems for academic research institutions, clinical laboratories, pharmaceutical companies, and biotechnology and Ag-Bio companies |
| Public (Nasdaq:FLDM) | M&A | Buy-Side | Acquired DVS Sciences | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-02-27 | 0 | | KnowledgePoint360 Group | Secaucus, NJ
Provides healthcare information and communications solutions, and advisory services for the pharmaceuticals and biotech industries |
| Private | M&A | Sell-Side | Sold to UDG Healthcare | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-02-24 | 0 | | Global Healthcare Exchange, Inc. | Louisville, CO
Provider of connected, intelligent healthcare supply chain automation solutions |
| Private | M&A | Sell-Side | Sold to Thoma Bravo | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-02-21 | 0 | | Emergent BioSolutions, Inc. | Rockville, MD
A biopharmaceutical company engaged in the development, manufacture, and commercialization of vaccines and therapeutics for use in defense and commercial markets to healthcare providers and purchasers. |
| Public (NYSE:EBS) | M&A | Buy-Side | Acquired Cangene Corporation | Financial Advisor | NYSE:EBS | Undisclosed | Healthcare |
| M&A | 2014-02-14 | 0 | | Reliant HealthCare Professionals | Greenwood Village, CO
Provides healthcare staffing services and professionals to facilities in Colorado. |
| Private | M&A | Sell-Side | Sold to Altaris Capital Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-02-03 | 0 | | Cabochon Aesthetics, Inc. | Menlo Park, CA
Minimally invasive cellulite elimination devices |
| Private | M&A | Sell-Side | Sold to Ulthera | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-01-28 | 0 | | LUMOS INC. | Lindon, UT
Designs and develops sports medicine products for individuals, athletes, medical/healthcare professionals, and teams worldwide |
| Private | M&A | Sell-Side | Sold to Palladin Consumer Retail Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-01-23 | 0 | | Solta Medical | Hayward, CA
Medical aesthetics company |
| Public (Nasdaq:THRM) | M&A | Take Private | Sold to Valeant Pharmaceuticals (TSX: VRX) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2014-01-13 | 0 | | Aerial BioPharma | Morrisville, NC
Engages in drug development for central nervous system |
| Private | M&A | Sell-Side | Sold its rights to ADX-N05 to Jazz Pharmaceuticals (Nasdaq:JAZZ) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-12-31 | 0 | | BGS Pharmacy Partners, Inc | Grapevine, TX
Pharmaceutical services provider. |
| Private | M&A | Sell-Side | Sold to PharMerica Corporation (NYSE: PMC) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-12-31 | 0 | | AtriCure, Inc. | West Chester, OH
Develops, manufactures, and sells cardiac surgical ablation systems |
| Public (Nasdaq:ATRC) | M&A | Buy-Side | Acquired Endoscopic Technologies, Inc. ("Estech") | Financial Advisor | Nasdaq:ATRC | Undisclosed | Healthcare |
| M&A | 2013-12-30 | 222.0 | | TyRx Inc. | Monmounth Junction, NJ
Antimicrobial mesh pouch for infection prevention. |
| Private | M&A | Sell-Side | Sold to Medtronic, Inc. (NYSE:MDT) | Financial Advisor | | 222.0 | Healthcare |
| M&A | 2013-12-16 | 0 | | TAP Biosystems | Royston, UK,
Leading global provider of automated cell culture and single-use micro-scale fermentation systems |
| Private | M&A | Sell-Side | Sold to Sartorius Stedim Biotech GmbH | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-11-27 | 0 | | One Call Medical Inc. | Parsippany, NJ
Provides specialized services to the workers? compensation industry by connecting patients to providers of medical and other specialized services. |
| Private | M&A | Sell-Side | Sold to Apax Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-11-14 | 0 | | Rochester Medical Corporation | Stewartville, MN
Develops, manufactures, and markets urinary continence and urine drainage care products for the home care and acute/extended care markets. |
| Public (Nasdaq:ROCM) | M&A | Take Private | Sold to C. R. Bard Inc. (NYSE:BCR) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-11-13 | 0 | | Lanx LLC | Broomfield, CO
Fusion devices for all segments of spinal surgery. |
| Private | M&A | Sell-Side | Sold to Biomet Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-10-31 | 0 | | IVESCO Holdings LLC | Iowa Falls, IA
Distributes animal health products in the United States. |
| Private | M&A | Sell-Side | Sold to MWI Veterinary Supply Co. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-10-29 | 0 | | Apollo Endosurgery, Inc. | Austin, TX
Offers a product suite of surgical products from the convergence of laparoscopic surgery and therapeutic gastroenterology. |
| Private | M&A | Buy-Side | Acquired Allergan, Inc.?s Obesity Intervention Business, including the Lap-Band. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-08-30 | 0 | | Physicians Endoscopy, LLC | Doylestown, PA
A leading developer and manager of freestanding ambulatory surgery centers. |
| Private | M&A | Sell-Side | Sold to Pamlico Capital Partners | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-08-30 | 0 | | Imds, Inc. | Fort Worth, TX
Provides medical device development and manufacturing services for the orthopedic industry. |
| Private | M&A | Sell-Side | Sold to CoorsTek, Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-08-21 | 0 | | IDev Technologies, Inc. | Houston, TX
Develops and markets medical devices for use in interventional radiology, gastroenterology, vascular surgery, and cardiology device marketplaces. |
| Private | M&A | Sell-Side | Sold to Abbott Laboratories (NYSE:ABT) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-03-12 | 0 | | Epocrates Inc. | San Mateo, CA
Develops mobile and Web-based clinical solutions for physicians and medical students |
| Public (Nasdaq:EPOC) | M&A | Take Private | Sold to athenahealth, Inc. (Nasdaq:ATHN) | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-01-15 | 0 | | NDS Surgical Imaging | San Jose, CA
Engages in the design and manufacture of medical imaging and informatics systems for operative and interventional suites |
| Private | M&A | Sell-Side | Sold to GSI Group Inc. | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-01-10 | 0 | | MorphoSys UK Ltd. (AbD Serotec) | Oxford, UK,
Manufactures and supplies antibodies, kits, and accessories worldwide |
| Private | M&A | Sell-Side | Sold to Bio-Rad Laboratories | Financial Advisor | | Undisclosed | Healthcare |
| M&A | 2013-01-03 | 0 | | National Seating & Mobility, Inc. | Nashville, TN
Provider of Complex Rehab Technology (CRT) mobility solutions |
| Private | M&A | Sell-Side | Sold to Wellspring Capital Management | Financial Advisor | | Undisclosed | Healthcare |
| Private Placement | 2020-07-08 | 30.0 | Cutera, Inc. | Public (Nasdaq:CUTR) | Private Placement | Subordinated Debt | Piper Sandler served as sole debt placement agent for Cutera, Inc. on debt capital raise from Silicon Valley Bank, Inc. | Sole Placement Agent | Nasdaq:CUTR | 30.0 | Healthcare |
| Private Placement | 2020-04-29 | 25.0 | | Evofem Biosciences, Inc. | San Diego, CA
|
| Public (Nasdaq:EVFM) | Private Placement | Subordinated Debt | Piper Sandler served as exclusive financial advisor for Evofem on a private placement with Baker Brothers, a healthcare-focused institutional investor for up to $25 million of convertible notes | Financial Advisor | Nasdaq:EVFM | 25.0 | Healthcare |
| Private Placement | 2019-08-09 | 30.0 | | Sight Sciences, Inc. | Menlo Park, CA
|
| Private | Private Placement | Preferred Equity | Piper Jaffray served as sole equity placement agent for Sight Sciences on $20 million convertible preferred equity financing to fund commercialization efforts | Sole Financial Advisor | | 30.0 | Healthcare |
| Private Placement | 2019-06-28 | 75.0 | | Saluda Medical Pty Ltd. | Artarmon, NSW
|
| Private | Private Placement | Preferred Equity | Piper Jaffray served as exclusive financial advisor for Saluda Medical on $75 million equity financing from Boston Scientific Corporation and Redmile Group LLC | Financial Advisor | | 75.0 | Healthcare |
| Private Placement | 2019-04-11 | 235.0 | | Asklepios BioPharmaceutical, Inc. | Chapel Hill, NC
|
| Private | Private Placement | Preferred Equity | Piper Jaffray served as exclusive financial advisor for Asklepios BioPharmaceutical, Inc. on Series A Preferred Equity investment from TPG Global, LLC and Vida Ventures, LLC for a minority stake | Financial Advisor | | 235.0 | Healthcare |
| Private Placement | 2019-03-21 | 37.5 | | Ocular Therapeutix, Inc. | Bedford, MA
|
| Public (Nasdaq:OCUL) | Private Placement | Subordinated Debt | Piper Jaffray served as sole placement agent on a $37.5 million subordinated convertible debt financing | Sole Placement Agent | | 37.5 | Healthcare |
| Private Placement | 2018-12-14 | 0 | | Ionetix Corporation | San Francisco, CA
|
| Private | Private Placement | Preferred Equity | Piper Jaffray served as sole placement agent for Ionetix Corporation on Series F preferred equity raise | Sole Financial Advisor | | Undisclosed | Healthcare |
| Private Placement | 2017-12-19 | 0 | | Centinel Spine, Inc. | West Chester, PA
|
| Private | Private Placement | Subordinated Debt | Piper Jaffray served as sole placement agent for Centinel Spine on their capital raise | Financial Advisor | | Undisclosed | Healthcare |
| Private Placement | 2017-10-13 | 127.2 | | Personal Genome Diagnostics, Inc. | Baltimore, MD
|
| Private | Private Placement | Preferred Equity | Piper Jaffray served as the exclusive financial advisor and placement agent for Personal Genome Diagnostics, Inc. on capital raise | Financial Advisor | | 127.2 | Healthcare |
| Private Placement | 2017-04-07 | 18.0 | | Ortho Kinematics | Austin, TX
Medical technology company, focused on spine imaging informatics and committed to the idea that spine motion matters. |
| Private | Private Placement | Common Equity | Series D capital investment | Financial Advisor | | 18.0 | Healthcare |
| Private Placement | 2016-01-20 | 32.0 | | bioTheranostics, Inc. | San Diego, CA
Discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer. |
| Private | Private Placement | Preferred Equity | Raised $32 million Series A preferred equity from MVM Life Science Partners | Financial Advisor | | 32.0 | Healthcare |
| Private Placement | 2015-06-04 | 0 | | Calhoun Vision, Inc. | Pasadena, CA
Provides light adjustable lenses for use in cataract surgery. |
| Private | Private Placement | Preferred Equity | | Financial Advisor | | Undisclosed | Healthcare |
| Private Placement | 2014-10-28 | 40.0 | | Blue Belt Technologies, Inc. | Plymouth, MN
Provides and commercializes devices for computer-assisted surgery and diagnosis. |
| Private | Private Placement | Preferred Equity | $40 million senior secured debt and warrants | Sole Placement Agent | | 40.0 | Healthcare |
| Private Placement | 2014-10-21 | 20.0 | | Respicardia, Inc. | Minnetonka, MN
Develops implantable therapies to improve respiratory rhythm management and cardiovascular health of sleep disorder and heart failure patients. |
| Private | Private Placement | Common Equity | $20 million strategic financing from Sorin SpA | Sole Placement Agent | | 20.0 | Healthcare |
| Private Placement | 2013-12-03 | 10.0 | | TiGenix N.V. | Leuven, Belgium,
Biomedical company, engages in the development and commercialization of cell therapy products for the treatment of damaged and diseased tissues. |
| Public (ENXTBR:TIG) | Private Placement | Common Equity | EUR $10 million capital raise | Sole Placement Agent | ENXTBR:TIG | 10.0 | Healthcare |
| Private Placement | 2013-10-30 | 42.0 | | CVRx, Inc | Minneapolis, MN
Develops implantable technology for the treatment of high blood pressure. |
| Private | Private Placement | Preferred Equity | $42 million Series F Preferred capital raise | Sole Placement Agent | | 42.0 | Healthcare |
| Private Placement | 2013-06-13 | 22.0 | | MDX Medical Inc. (Vitals.com) | Lyndhurst, NJ
Provider of comprehensive medical information on doctors in the United States. |
| Private | Private Placement | Preferred Equity | $22 million Series C Convertible Preferred capital raise | Sole Placement Agent | | 22.0 | Healthcare |
| Private Placement | 2013-04-10 | 15.0 | | Lanx LLC | Broomfield, CO
Fusion devices for all segments of spinal surgery |
| Private | Private Placement | Preferred Equity | $15 million Series C Convertible Preferred capital raise | Sole Placement Agent | | 15.0 | Healthcare |
| Restructuring | 2020-12-11 | 270.0 | VIVUS Inc. | | Restructuring | In-Court | Piper Sandler served as investment banker to VIVUS, Inv. on its Chapter 11 Plan of Reorganization | Financial Advisor | | 270.0 | Healthcare |
| Restructuring | 2019-03-06 | 0 | | Synergy Pharmaceuticals, Inc. | New York, NY
|
| Public (Nasdaq:SGYP) | Restructuring | In-Court | Piper Jaffray served as exclusive advisor for CRG Servicing, LLC on sale of Synergy Pharmaceuticals, Inc. to Bausch Health Companies, Inc. through a Chapter 11 §363 sale | Sole Financial Advisor | | Undisclosed | Healthcare |
| Restructuring | 2019-01-31 | 0 | | Egalet Corporation | Wayne, PA
|
| Public (OTC:EGLT) | Restructuring | In-Court | Piper Jaffray served as exclusive investment banking financial advisor for Egalet Corporation on Chapter 11 reorganization | Sole Financial Advisor | | Undisclosed | Healthcare |
